Response Adaptive Randomization using Surrogate and Primary Endpoints by Wang, Hui
Virginia Commonwealth University 
VCU Scholars Compass 
Theses and Dissertations Graduate School 
2016 
Response Adaptive Randomization using Surrogate and Primary 
Endpoints 
Hui Wang 
Follow this and additional works at: https://scholarscompass.vcu.edu/etd 
 Part of the Medicine and Health Sciences Commons 
 
© The Author 
Downloaded from 
https://scholarscompass.vcu.edu/etd/4517 
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It 
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars 
Compass. For more information, please contact libcompass@vcu.edu. 
Response Adaptive Randomization
using Surrogate and Primary
Endpoints
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
by
Hui Wang
Director: Nitai Mukhopadhyay, Ph.D., Associate Professor, Department of Biostatistics
Department of Biostatistics
Virginia Commonwealth University
Richmond, Virginia
August, 2016
Acknowledgements
First of all, I would like to express my deepest appreciation to my thesis advisor, Dr.
Nitai D. Mukhopadhyayi for his encouragement and persistent help throughout the
course of my thesis. I thank him for the systematic guidance and great effort he put
into training me in the scientific field.
I would also like to thank my committee members, Dr. Donna McClish, Dr. Roy
Sabo, Dr. Amy Pakyz, and Dr. Susie Sinks for their commitment to my dissertation.
I appreciate their comments and suggestions. To Dr. McClish, thanks for being
my academic advisor and giving me advice on my graduate study. And thank Dr.
Pakyz for providing me the opportunity to work as a research assistant at School of
Pharmacy for the past two years. I also appreciate the kindness, support, and help
from my classmates and the rest of faculty and staff in the department.
Finally, I thank my family, especially my parents and my uncle and aunt, without
whose support, encouragement, and love, I would not have finished this thesis.
i
Contents
1 Introduction 1
1.1 Adaptive Design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Response Adaptive Randomization . . . . . . . . . . . . . . . . . . . 3
1.3 Motivation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.4 Organization of this thesis . . . . . . . . . . . . . . . . . . . . . . . . 8
2 Current statistical approaches of response-adaptive randomization
for continuous outcomes 11
2.1 Doubly adaptive biased coin designs . . . . . . . . . . . . . . . . . . . 12
2.2 Optimal response-adaptive designs . . . . . . . . . . . . . . . . . . . 13
2.2.1 General approach . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.2.2 Allocations for normally distributed responses . . . . . . . . . 15
2.2.3 Allocations for survival responses . . . . . . . . . . . . . . . . 17
2.3 Delayed responses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
3 Bivariate Response Adaptive Design for Continuous Outcomes 22
3.1 Response adaptive randomization using primary endpoint only . . . . 23
ii
3.2 Proposed method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
3.2.1 Likelihood distribution . . . . . . . . . . . . . . . . . . . . . . 25
3.2.2 Prior distribution . . . . . . . . . . . . . . . . . . . . . . . . . 27
3.2.3 Estimation rule for allocation rate . . . . . . . . . . . . . . . . 31
3.2.4 Algorithm of the design . . . . . . . . . . . . . . . . . . . . . 33
3.3 Simulation study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
3.3.1 Simulation targets . . . . . . . . . . . . . . . . . . . . . . . . 35
3.3.2 Sampling method . . . . . . . . . . . . . . . . . . . . . . . . . 36
3.3.3 Simulation settings . . . . . . . . . . . . . . . . . . . . . . . . 37
3.3.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
4 Response Adaptive Design for Clinical Trials with Time-to-Event
Outcomes using Surrogate Endpoint 55
4.1 RAR using primary outcome only . . . . . . . . . . . . . . . . . . . . 56
4.2 Proposed method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
4.2.1 The finite mixture framework . . . . . . . . . . . . . . . . . . 59
4.2.2 Specifying the design parameters . . . . . . . . . . . . . . . . 60
4.3 Model fitting using MCMC . . . . . . . . . . . . . . . . . . . . . . . . 62
4.3.1 Label switching . . . . . . . . . . . . . . . . . . . . . . . . . . 63
4.3.2 Prior distribution . . . . . . . . . . . . . . . . . . . . . . . . . 64
4.3.3 Estimation procedure . . . . . . . . . . . . . . . . . . . . . . . 66
4.4 Algorithm of the design . . . . . . . . . . . . . . . . . . . . . . . . . 68
4.5 Simulation study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
iii
4.5.1 Simulation targets . . . . . . . . . . . . . . . . . . . . . . . . 70
4.5.2 Sampling method . . . . . . . . . . . . . . . . . . . . . . . . . 71
4.5.3 Simulation settings . . . . . . . . . . . . . . . . . . . . . . . . 72
4.5.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
4.6 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
5 Discussion and Future Work 87
Bibliography 91
Appendix 96
A Chapter 3 appendix 96
A.1 Bivariate normal distribution model in JAGS . . . . . . . . . . . . . . 96
A.2 Proposed response adaptive randomization procedure for normally dis-
tributed primary outcome . . . . . . . . . . . . . . . . . . . . . . . . 98
B Chapter 4 appendix 107
B.1 Mixture model in JAGS . . . . . . . . . . . . . . . . . . . . . . . . . 107
B.2 Proposed response adaptive randomization procedure for survival re-
sponse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
iv
List of Tables
3.1 Parameters in the bivariate normal distribution model . . . . . . . . . 38
3.2 Parameter setup for different experimental scenario . . . . . . . . . . 46
3.3 Summary of power of the three randomization procedures using the
two-sided two-sample t-test . . . . . . . . . . . . . . . . . . . . . . . 47
3.4 Summary of average number of subjects assigned to treatment A, with
standard deviations (SD) for the three randomization procedures . . 48
3.5 Summary of observed allocation proportion of treatment A, with stan-
dard deviations (SD) for the three randomization procedures . . . . . 49
3.6 Summary of observed total responses, with standard deviations (SD)
for the three randomization procedures . . . . . . . . . . . . . . . . . 50
3.7 Summary of power of the three randomization procedures using the
two-sided two-sample t-test . . . . . . . . . . . . . . . . . . . . . . . 51
3.8 Summary of average number of subjects assigned to treatment A, with
standard deviations (SD) for the three randomization procedures . . 52
3.9 Summary of observed allocation proportion of treatment A, with stan-
dard deviations (SD) for the three randomization procedures . . . . . 53
v
3.10 Summary of observed total responses, with standard deviations (SD)
for the three randomization procedures . . . . . . . . . . . . . . . . . 54
4.1 Parameter setup for different experimental scenario . . . . . . . . . . 81
4.2 Summary of power of the three randomization procedures using the
two-sided Wald test . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
4.3 Summary of average number of subjects assigned to treatment A, with
standard deviations (SD) for the three randomization procedures . . . 83
4.4 Summary of observed allocation proportion to treatment A, with stan-
dard deviations (SD) for the three randomization procedures . . . . . 84
4.5 Summary of average number of events, with standard deviations (SD)
for the three randomization procedures . . . . . . . . . . . . . . . . . 85
4.6 Summary of total observed survival time, with standard deviations
(SD) for the three randomization procedures . . . . . . . . . . . . . . 86
vi
List of Figures
2.1 The effect of delay on treatment allocation when using standard re-
sponse adaptive randomization. . . . . . . . . . . . . . . . . . . . . . 20
3.1 Comparison of the variation of the standard RAR method and pro-
posed RAR algorithm for handling delayed primary outcomes with
(λ1, λ2, λ3) = (10, 10, 1). . . . . . . . . . . . . . . . . . . . . . . . . . 44
3.2 Comparison of the variation of the standard RAR method and pro-
posed RAR algorithm for handling delayed primary outcomes with
(λ1, λ2, λ3) = (80, 80, 1). . . . . . . . . . . . . . . . . . . . . . . . . . 45
vii
Abstract
RESPONSE ADAPTIVE RANDOMIZATION USING SURROGATE AND
PRIMARY ENDPOINTS
By Hui Wang
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2016
Major Director: Nitai Mukhopadhyay, Ph.D., Associate Professor, Department of
Biostatistics
In recent years, adaptive designs in clinical trials have been attractive due to their
efficiency and flexibility. Response adaptive randomization procedures in phase II
or III clinical trials are proposed to appeal ethical concerns by skewing the proba-
bility of patient assignments based on the responses obtained thus far, so that more
patients will be assigned to a superior treatment group. General response-adaptive
randomizations usually assume that the primary endpoint can be obtained quickly
after the treatment. However, in real clinical trials, the primary outcome is delayed,
making it unusable for adaptation. Therefore, we utilize surrogate and primary end-
points simultaneously to adaptively assign subjects between treatment groups for
clinical trials with continuous responses. We explore two types of primary endpoints
commonly used in clinical tirials: normally distributed outcome and time-to-event
outcome. We establish a connection between the surrogate and primary endpoints
viii
through a Bayesian model, and then update the allocation ratio based on the ac-
cumulated data. Through simulation studies, we find that our proposed response
adaptive randomization is more effective in assigning patients to better treatments
as compared with equal allocation randomization and standard response adaptive
randomization which is solely based on the primary endpoint.
ix
Chapter 1
Introduction
1.1 Adaptive Design
Clinical trials are prospective intervention studies with human subjects to investi-
gate experimental drugs, new treatments, medical devices, or clinical procedures,
under rigorously specified conditions [Yin, 2013]. Traditionally, clinical trials are de-
signed with fixed sample size and allocation probabilities among treatment group. No
changes can be made while the trial goes on and accumulated information becomes
available. In 2006, the United States Food and Drug Administration (FDA) released
a critical path opportunities list which recommended the creation of innovative and
efficient clinical trials that apply the accumulated information in the trial design
[Food et al., 2007]. Specidically, the FDA began encouraging the use of adaptive
design methods in clinical trials.
Adaptive designs in clinical trials are attractive due to their efficiency and flex-
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ibility. However, there is no universal definition of it. In 2006, the pharmaceutical
research and Manufacturers of America (PhRMA) defined an adaptive design as a
clinical trial design that uses accumulating data to decide on how to modify as-
pects of the study as it continues, without undermining the validity and integrity of
the trial[Gallo et al., 2006]. Based on this definition, adaption is the main feature
to improve the design. In 2010, the U.S. Food and Drug Administration (FDA)
released a guidance on the regulatory aspects of adaptive designs[Administration
et al., 2010]. The FDA explains that there is great interest in the possibility that
clinical trials can be designed with adaptive features that may make the studies
more efficient (e.g., shorter duration, fewer patients), more likely to demonstrate a
treatment effect, or more informative (e.g., broader dose-response findings). In the
guidance, the adaptive design clinical study is referred to as a study that includes a
prospectivly planned opportunity for modification of one or more specified aspects
of the study design and hypotheses based on analysis of data (usually interim data)
from subjects in the study. Based on adaptations employed in general, commonly
considered adaptive design methods in clinical trials include adaptive randomiza-
tion, group sequential methods, sample size re-estimation, adaptive dose finding,
adaptive treatment-switching, etc[Chow et al., 2008]. Another way of classifying
adaptive design clinical trials is by categorizing them based on four different rules:
Allocation rule, sampling rule, stopping rule, and decision rule[Mahajan and Gupta,
2010]. Allocation rules define how subjects are allocated to different arms in a trial,
which includes response-adaptive randomization and covariate adaptive allocation.
Sampling rules define how many subjects will be sampled at the next stage, which
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includes sample size re-estimation and drop-the-loser designs. Stopping rules de-
fine when to stop the trial, which includes group sequential design and adaptive
treatment-switching design. Decision rules refer to changes not covered under the
other three categories, which may include hypothesis-adaptive design and change the
primary end-point or statistical method or patient population design.
1.2 Response Adaptive Randomization
In clinical trials, patients are assigned to different groups to receive different treat-
ments. The process of assigning patients to different groups by chance is called
randomization. The primary goal of randomization is to prevent bias in allocat-
ing subjects to treatment groups, thereby obtaining a credible and unbiased result.
Traditionally, equal randomization or randomization with a fixed ratio (e.g. 1 : 3)
among the groups are commonly used in clinical trials. The main feature of tradi-
tional randomization is that the probability of assigning patient to each treatment
group is fixed and pre-determined. Even through when the trial proceeds, one may
find that the treatment group performs better than the control group, the allocation
probability can never be changed. However, there is one ethical concern that more
patients should be assigned to the better treatment group if evidence of superior-
ity exists. Recently, the response adaptive randomization or RAR becomes popular
since it can change the allocation probabilities when the trial goes on.
Response-adaptive randomization procedures in clinical trials are proposed to
appeal the ethical concerns by skewing the probability of patient assignments based
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on the responses obtained thus far, so that more patients will be assigned to a
superior treatment group[Zhang and Rosenberger, 2006]. The preliminary ideas of
response adaptive design was proposed by Thompson (1933) and Robins (1952), and
have been further developed by other researchers. Most of the available works in
adaptive randomization designs have been focused on binary outcomes[Biswas and
Bhattacharya, 2012]. Examples include the play-the-winner rule (Zelen, 1969), the
randomized play-the-winner rule (Wei and Durham, 1978), the success-driven design
(Durham, Flournoy and Li, 1998), the drop-the-loser design (Ivanova, 2003), and the
generalized drop-the-loser design (Zhang, Chan and Cheung, 2007), etc. However,
many real clinical trials need to deal with continuous outcomes. For example, Wilson
et al. (1998) used office-recorded diastolic blood pressure reduction, which may be
considered to have an approximate normal distribution, as the primary outcome to
evaluate the antihypertensive efficacy of losartan and amlodipine[Wilson et al., 1998].
Fu et al. (1998) considered wound healing time, which is a time to event outcome,
as the primary outcome to evaluate the efficacy of topical recombinant bovine basic
fibroblast growth factor for second-degree burns[Fu et al., 1998].
In 1993, Rosenberger introduced a reasonable allocation design for the case of
general (not necessarily dichotomous) responses[Rosenberger et al., 1993]. He used
the idea of treatment effect mapping, in which the allocation probabilities are func-
tions of the current estimate of treatment effect. This method can be used for clini-
cal trials with continuous responses to skew the allocation to the better treatment.
Later on, some other response-adaptive designs have been developed for continuous
responses in clinical trials, such as the continuous drop-the-loser rule, Wilcoxon-
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Mann-Whitney-type adaptive design, doubly adaptive biased coin designs (DBCD),
Kernel-based allocation designs, etc. Except for DBCD, all the other designs men-
tioned above are not based on any optimal consideration. For those designs which are
not based on any optimality criteria, they may have high variability which may lead
to significant loss in power[Zhang and Rosenberger, 2006]. When a smaller response
is desirable, Zhang and Rosenberger (2006) suggested that the DBCD procedure with
optimal allocation can reduce total expected response and simultaneously maintain
power, and should be the first choice for response-adaptive randomization designs
with continuous outcome. So our response-adaptive design will be an extension of
the doubly adaptive biased coin design procedure with optimal allocation. More
details of this procedure will be discussed in Chapter 2.
1.3 Motivation
The general response-adaptive randomization mentioned above assumes that the pri-
mary endpoint can be obtained quickly after the treatment. However, in real clinical
trials, and not only for survival outcomes, one may need to take a relatively long
time to observe the primary endpoints. Some studies have been done on delayed
primary endpoints and their effect on response-adaptive randomization in the liter-
ature. Zhang and Rosenberger (2006) explored the effect of delayed responses on
response-adaptive randomization for continuous outcomes based on some simulation
studies[Zhang and Rosenberger, 2006]. They found that moderate delays in responses
have little effect on the power and asymptotic properties of the DBCD procedure.
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Later on, Hu et al. studied the effects of delayed responses in DBCD mathemati-
cally[Hu et al., 2008]. They found that the asymptotic properties of the allocation
proportions are unaffected by staggered entry and delayed responses in reasonable
probability models. Even though moderate delays in responses have no effect on the
asymptotic properties of randomization procedure under certain delay mechanisms,
the allocation rate through the trial is directly affected and there is a higher risk of
assigning more patients to the inferior treatment[Sinks, 2013].
We are motivated to propose a new response-adaptive randomization method
that incorporates one or more surrogate endpoints, that are correlated with the pri-
mary endpoint. In clinical trials, a biomarker is defined as a characteristic that
is objectively measured and evaluated as an indicator of normal biological pro-
cesses, pathogenic processes, or pharmacologic responses to a therapeutic interven-
tion[Group, 2001]. A surrogate endpoint is a biomarker that is intended to substi-
tute for a clinical endpoint. Even though a surrogate endpoints can be selected so
that it is measured earlier than the primary endpoint, the incorporation of that in
response-adaptive randomization has not been fully explored. Huang et al. (2009)
perhaps are the first who use short-term response information to facilitate adaptive
randomization in clinical trials. They proposed a new design for survival trials that
connects short-term response with long-term survival to ’speed up’ the adaptation of
the randomization procedure[Huang et al., 2009]. In their study, they assume that
conditional on the categorical short-term responses, the long-term response follows
an exponential distribution. However, they didn’t optimize the allocation design in
their study. Sinks (2013) proposed a bivariate response adaptive design for binary
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primary endpoint where a binary auxiliary endpoint was used to assist the adapta-
tion with the primary endpoint [Sinks, 2013]. She found that the bivariate adaptive
design was more effective in assigning patients to better treatments as compared
with univariate optimal and balanced designs. Rencently, Nowacki et al. (2015) pro-
posed a surrogate-primary (S-P) replacement algorithm where a patent’s surrogate
outcome is used in the response-adaptive randomization only until their primary out-
come becomes available to replace it[Nowacki et al., 2015]. They showed that the S-P
replacement algorithm performs better than the standard approach by reducing the
probability variability and increasing convergence of the treatment allocation ratio
toward its target.
In my dissertation study, we will focus on clinical trials with continuous pri-
mary outcomes. We assume that there is a delay in the primary endpoint, but the
surrogate endpoint which is associated with the primary endpoint can be observed
immediately. We will propose a new response-adaptive randomization method that
will utilize surrogate and primary endpoints at the same time for clinical trials with
continuous primary responses. The connection of surrogate and primary endpoints
is established through a Bayesian model. We will draw inferences about parameters
of interest through a Markov Chain Monte Carlo (MCMC) simulation. Then these
parameters will be used to calculate the desired target allocation to estimate the
optimal proportion for allocating subjects between treatments. Finally, we will use
these sequentially estimated proportions based on DBCD rule to skew the allocation.
Details will be discussed in later chapters.
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1.4 Organization of this thesis
In Chapter 2, we will review some current statistical approaches of response adap-
tive randomization for clinical trials with continuous outcomes. These approaches are
solely based on the primary endpoint, and always assume that the primary endpoint
can be observed immediately after treatment. Even through researchers have shown
that for continuous response, the delayed response has no effect on the asymptotic
properties of the randomization procedure under very general conditions, we still
believe that the delay in the primary response will influence the performance of the
standard response adaptive randomization, where only the accumulated information
from primary endpoint is considered during the randomization procedure. To illus-
trate this issue, we will conduct some simulation studies with different proportion
of delays in the primary endpoint to show the drawback of the standard response
adaptive randomization.
In Chapter 3, we will consider a clinical trial where both surrogate and primary
endpoints have a normal distribution and propose a new response adaptive random-
ization procedure which will extend the standard adaptive randomization design for
normally distributed continuous outcomes to simultaneously account for the surro-
gate endpoint. We will refer to the allocation procedure proposed by Zhang and
Rosenberger[Zhang and Rosenberger, 2006] as the univariate optimal adaptive de-
sign for continuous outcomes. Under this procedure, the optimal allocation ratio
is obtained by minimizing the total expected response of patients if we assume a
lower response is desirable. To implement the surrogate endpoint in the adaptation
process, we assume that the surrogate and primary endpoints follow a bivariate nor-
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mal distribution. Thus given the surrogate endpoint, the conditional distribution of
the primary endpoint will also be normal. We will start with the conditional model
of primary endpoint given surrogate to perform the adaptive randomization proce-
dure. Conjugate priors will be given to the parameters in the conditional model. The
allocation ratio for each subject will be calculated based on the posterior mean of pa-
rameters in the conditional model. A simulation study will be performed to compare
the performance, specifically in power and treatment assignment skewing to better
treatment, of simple randomization, univariate optimal adaptive randomization, and
bivariate optimal adaptive randomization.
In Chapter 4, we will focus on clinical trials where the primary endpoint is a
time-to-event outcome. Specifically, we assume that the primary endpoint follows
an exponential distribution and there is a categorical surrogate endpoint that can be
obtained immediately after the treatment. Then we will propose a new randomiza-
tion algorithm which will extend the standard adaptive randomization for survival
trials to simultaneously account for a binary surrogate endpoint. We will refer to the
allocation procedure proposed by Zhang and Rosenberger as the univeriate optimal
adaptive design for survival outcomes [Zhang and Rosenberger, 2007]. Under this
procedure, the optimal allocation proportion is obtained by minimizing the total
expected hazard. To implement the surrogate endpoint in the randomization proce-
dure, we assume that the surrogate endpoint follows a multinomial distribution and
given the surrogate endpoint, the primary endpoint follows a mixture of exponential
distribution. We will estimate the parameters of interest through a Bayesian model,
and then apply these estimates to the optimal allocation function to skew the al-
9
location probability. The performance of the proposed algorithm will be evaluated
through a series of simulations.
In Chapter 5, we will discuss the two randomization procedures we proposed in
the previous two chapters, and some future works that can be done.
10
Chapter 2
Current statistical approaches of
response-adaptive randomization
for continuous outcomes
Response-adaptive designs can be classified into two categories. The first is the
target-driven response-adaptive design that is based on an optimal allocation tar-
get, where a specific criterion is optimized based on a population response model.
The second class is the design-driven response-adaptive randomization, where al-
location rules are established with an intuitive motivation, but not optimal in a
formal sense[Rosenberger and Lachin, 2004]. In this dissertation study, the proposed
randomization procedure in chapter 3 and chapter 4 will be based on the first cate-
gory, which is target-driven response adaptive randomization. So in this chapter, we
are only going to review some commonly used optimal response-adaptive designs in
11
clinical trials with continuous outcome.
2.1 Doubly adaptive biased coin designs
Doubly adaptive biased coin design (DBCD) is a family of response-adpative pro-
cedures that can be used to target a desired allocation proportion ρ. It was first
proposed by Eisele in 1994 and then sequentially modified by some other researchers
[Eisele and Woodroofe, 1995].
Eisele (1994) and Woodroffe (1995) proposed a DBCD procedure for two treat-
ment groups to target any desired allocation proportion ρ to treatment A. They
defined a function g(x, y) on [0, 1]2 × [0, 1] which needs to satisfy the following con-
ditions:
(i) g is jointly continuous;
(ii) g(x, x) = x,
(iii) g(x, y) is strictly decreasing in x and strictly increasing in y on [0, 1]2, and
(iv) g has bounded derivatives in both arguments.
Suppose j subjects have been randomized to the two treatment groups, then the
DBCD procedure will allocate the (j + 1)th subject to treatment A with probability
g(nAj/j, ρˆj), where nAj is the number of subjects assigned to treatment A so far,
and ρˆj is the estimated target allocation proportion based on the first j subjects.
Thus, the double adaptive biased coin design (DBCD) depends on both the current
observed allocation proportion and the estimate of target allocation proportion.
The key component of this procedure is the choice of an appropriate allocation
12
function g(x, y). Hu and Zhang (2004) proposed the following family of allocation
function:
g(α)(x, y) =

1 if x = 0
y( y
x
)α
y( y
x
)α+(1−y)( 1−y
1−x )
α
if 0 < x < 1
0 if x = 1
where α ≥ 0 and controls the degree of randomness of the procedure[Hu and Zhang,
2004]. Different choices of α lead to different allocation procedures. For example, if
α = 0, then g(α)(x, y) = y and we will have the Sequential Maximum Likelihood Esti-
mation, where at each stage the target allocation proportion is estimated, preferably
by the maximum likelihood method, and the next incoming subject will be assigned
to treatment A with this probability. In general, a DBCD procedure with a large
value of α will provide a smaller variance but will decrease the degree of random-
ness[Biswas and Bhattacharya, 2012]. Therefore, α should be chosen to reflect the
trade-off between the degree of randomness and the variation [Atkinson and Biswas,
2013]. Suppose NA is the number of subjects assigned to treatment A and n is the
total sample size. Hu and Zhang (2004) showed that under mild conditions, both
NA/n and ρˆ converge to ρ almost surely, and have an asymptotic bivariate normal
distribution.
2.2 Optimal response-adaptive designs
As we mentioned before in section 2.1, the double adaptive biased coin design
(DBCD) depends on the target allocation proportion. For ethical consideration in
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response-adaptive randomization in clinical trials, it is desired to target an allocation
proportion which is optimal in some sense[Zhang and Rosenberger, 2006].
2.2.1 General approach
To develop an optimal allocation design, we need to define a clinically relevant cri-
terion and then try to optimize it. In 2007, Biswas et al. proposed a general ap-
proach to obtain the optimal target allocation for clinical trials with continuous
outcomes[Biswas et al., 2007]. Consider a clinical trial with two treatment groups
and let k be the treatment indicator, where k = 1, 2. Let Xk be the primary out-
come which is assumed to have a continuous distribution with mean µk and finite
variance σ2k, k = 1, 2. Let n1 and n2 be the sample sizes for the two treatments
in a non-randomized manner. Then for the general approach, one may choose to
minimize
n1Ψ1 + n2Ψ2
subject to the restriction
σ21
n1
+
σ22
n2
= K
where Ψk is a positive function of (µk, σk), which will be different for different goal
of the trial, and K is a constant. Solving this optimization problem, we can obtain
the optimal allocation proportion to treatment 1 as below:
ρ =
σ1
√
Ψ2
σ1
√
Ψ2 + σ2
√
Ψ1
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Here, ρ depends on unknown parameters and these unknown parameters can be
estimated through either frequentist or Bayesian method.
2.2.2 Allocations for normally distributed responses
Now consider the situation where the primary endpoint has normal distribution. We
assume that the primary outcomes for each treatment group are normally distributed
with X1 ∼ N(µ1, σ21) and X2 ∼ N(µ2, σ22), respectively. Without loss of generality, we
assume that a small response is desirable. As we mentioned before, different choices
of Ψ1 = g(µ1, σ1) and Ψ2 = g(µ2, σ2) can be made, and these Ψ1 and Ψ2 reflect
different goals or targets of the trial. So far, only a few optimal adaptive designs
are available for continuous responses with normal distribution. In this section, we
will summarize some of these available allocation proportions that are commonly
discussed in the literature.
If Ψk = 1 for each of the two treatment groups, then the optimization problem is
to minimize the total sample size for a fixed variance of the estimated treatment dif-
ference[Biswas and Bhattacharya, 2012]. The solution for this optimization problem
is the well-known Neyman allocation which can be expressed as
ρ =
σ1
σ1 + σ2
(2.1)
where ρ is the optimal allocation proportion to treatment 1.
If we let Ψk = µk, for k = 1, 2, then the optimization problem is equivalent to
minimize the total expected response from all patients. This optimization problem
15
was proposed by Zhang and Rosenberger in 2006 [Zhang and Rosenberger, 2006].
Define r = σ1
√
µ2/σ2
√
µ1 and
s =

1 if ( µ1 < µ2 and r > 1) or (µ1 > µ2 and r < 1),
0 otherwise.
Then the optimal allocation proportion to treatment 1 for this problem will be
ρ =

σ1
√
µ2
σ1
√
µ2+σ2
√
µ1
if s = 1,
1
2
otherwise.
(2.2)
Furthermore, another choice of Φk could be Ψk = Φ(
µk−c
σk
) where c is a predefined
threshold constant and Φ(·) is the cumulative density function of standard normal
distribution. This optimization problem was proposed by Biswas and Mandal in
2004 and the aim is to minimize the total number of patients with response greater
than some threshold constant[Biswas and Mandal, 2004]. Solving this optimization
problem, we can obtain the optimal allocation proportion to treatment 1 as below:
ρ =
√
Φ(µ2−c
σ2
)σ1√
Φ(µ2−c
σ2
)σ1 +
√
Φ(µ1−c
σ1
)σ2
Zhang and Rosenberger (2006) compared the performance of the above three ran-
domization procedures through a simulation study, and they found that the DBCD
procedure with their optimal allocation proportion can reduce the total expected
response and simultaneously maintain the power, and thus should be the first choice
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for response adaptive randomization with continuous outcomes [Zhang and Rosen-
berger, 2006]. Thus in chapter 3, where the primary endpoint is assumed to be
normally distributed, we will extend the optimal allocation procedure proposed by
Zhang and Rosenberger in equation 3.1 to simultaneously account for the information
from surrogate endpoint.
2.2.3 Allocations for survival responses
For clinical trials with survival or time-to-event outcomes, inherent delay is com-
mon. Zhang and Rosenberger (2007) developed a response-adaptive randomization
procedure for survival outcomes with censoring and delay by using a parametric
approach that involves a target optimal allocation and a randomization procedure
with low variability[Zhang and Rosenberger, 2007]. Consider a clinical trial with two
treatment groups, and k is the treatment indicator, where k = 1, 2. Let nk be the
number of subjects assigned to treatment k. Now we assume that for the ith subject
in treatment k, the survival time Tik follows an exponential distribution with mean
θk. Furthermore, let Ci be the censoring time and is assumed to be independent of
Tik. Then for each subject i, one observes a pair of random variables (tik, δik), where
tik = min(Tik, Ci) is the observed time and δik is an indicator of event (δik = 1 if
the ith subject has an event; and δik = 0 if the ith subject is censored). Assume
k = E(δik) is the same for subjects in the same treatment group. Under the above
assumption, Zhang and Rosenberger (2007) proposed an optimal allocation propor-
tion where the target is to minimize the total expected hazard. The optimization
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problem can be stated below:

min
nA/nB
n1θ
−1
1 + n2θ
−1
2
s.t. θ21/n11 + θ
2
2/n22 = K
In this case, Ψk = θ
−1
k and σ
2
k =
θ2k
k
. And the corresponding optimal allocation
proportion to treatment 1 is
ρ =
√
θ312√
θ312 +
√
θ321
Another choice could be Ψk = 1 for k = 1, 2, and the aim is to minimize the
total number of subjects in the trial. Solving this problem will obtain the Neyman
allocation, where the optimal allocation proportion to treatment 1 is
ρ =
θ1
√
2
θ1
√
2 + θ2
√
1
2.3 Delayed responses
An important assumption for the double adaptive biased coin design was that the
primary outcome can be observed immediately after the treatment. However, it is
common that responses may not be available before the randomization of next sub-
ject and will be available after a period of time. Hu et al.(2008) examined the effect
of delayed responses on DBCD procedures and derived some of their asymptotic
properties[Hu et al., 2008]. Suppose that the subjects arrive sequentially in a clini-
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cal study, and the subjects delay time is not unreasonably large compared to their
arrival time, then they found out that under widely satisfied conditions for the delay
mechanism, the asymptotic properties of DBCD procedure remain insensitive to a
stochastic delay in updating the sequential estimator of the unknown parameters.
However, in real clinical trials, the delay in the primary endpoint will influence the
implementation of adaptive randomization. For example, when no primary outcome
becomes available for the next patient, then no information can be used to skew the
allocation proportion, and thus a simple randomization (e.g. equal allocation) needs
to be used for this patient. To illustrate this issue, we will conduct some simulations.
Consider a clinical trial with two treatment groups, and the primary outcome is
continuous. To be specific, suppose the primary outcome is normally distributed,
such that XA ∼ N(µA, σ2A), XB ∼ N(µB, σ2B), respectively. Furthermore, suppose
there is a constant enrollment rate. Therefore, there is a fixed delay time in the
primary endpoint. For example, to observe the primary outcome from the first
patient, 20 more patients enroll in the trial. Which means, the response of the first
patient will be available when the 21st patient enrolls in the trial, and the response
of the second patient will be available when the twenty second patient enrolls in
the trial, etc. Figure 2.1 shows the effect of delay in the primary responses for the
standard response adaptive randomization (only consider the primary endpoint).
As we can see from the plot, if there is no delay in the primary endpoint (all
the primary outcomes are available), then the proportion pf patients assigned to
treatment A is equal to the target allocation proportion. However, as the delay
in the primary endpoint increases (the proportion of primary outcomes available
19
Figure 2.1: The effect of delay on treatment allocation when using standard response
adaptive randomization.
decreases), the proportion of patients assigned to treatment A decreases. And when
there is no primary outcome available, the proportion equals to 0.5, which is the same
as the traditional equal randomization. This means that as the delay time increases,
the difference between the target allocation proportion and the observed allocation
proportion becomes larger, and thus the benefit of assigning more patients to a
better treatment group disappears. Moreover, we can also see from the plot that
the variability of the allocation proportion to treatment A is getting larger when
more primary outcomes become available. That is because the allocation probability
changes whenever a new patient enrolls.
The standard response adaptive randomization is influenced by the delay in the
20
primary endpoint. The benefit of assigning more patients to a better treatment group
disappears when there is a large delay time in the primary endpoint. Thus, we are
motivated to propose a new algorithm to simultaneously account for the information
from the surrogate endpoint, such that the benefit of assigning more patients to a
better treatment group will not disappear even when there is a large delay time in
the primary response.
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Chapter 3
Bivariate Response Adaptive
Design for Continuous Outcomes
In this chapter, we will propose a new response adaptive randomization for clinical
trials with normally distributed primary endpoint. In section 3.1, we will have a
brief review of the standard response adaptive randomization for clinical trials with
normally distributed primary endpoint. Then we will extend the standard adaptive
randomization procedure to simultaneously account for the information from the
surrogated endpoint by assuming a correlation between the surrogate and primary
endpoints in section 3.2. Finally in section 3.3, we will compare the proposed al-
gorithm with the standard response adaptive randomization and traditional equal
allocation procedure through some simulation studies.
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3.1 Response adaptive randomization using pri-
mary endpoint only
In the classical response adaptive procedure, consider a clinical trial with only two
treatment groups: Treatment A and Treatment B, and we want to compare the
difference between the two treatments with normally distributed responses, such
that TA ∼ N(µT,A, σ2t,A) and TB ∼ N(µT,B, σ2t,B), respectively. Suppose a smaller
response is desirable and we will consider the randomization procedure proposed
by Zhang and Rosenberger (2006) as the standard response adaptive randomization
(RAR), where the optimization problem is:

min
nA/nB
µT,AnA + µT,BnB
s.t.
σ2t,A
nA
+
σ2t,B
nB
= K
nA and nB refer to the cumulative number of subjects assigned to treatment A and
treatment B respectively, and K is some constant. Solving this problem yields the
optimal allocation proportion to treatment A as
ρ =
√
µT,Bσt,A√
µT,Bσt,A +
√
µT,Aσt,B
Then they defined r = σ1
√
µ2/σ2
√
µ1 and
s =

1 if ( µ1 < µ2 and r > 1) or (µ1 > µ2 and r < 1),
0 otherwise.
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and modified the optimal allocation proportion to treatment A as
ρ =

σ1
√
µ2
σ1
√
µ2+σ2
√
µ1
if s = 1,
1
2
otherwise.
(3.1)
As we mentioned before in Chapter 2, the Doubly Adaptive Biased Coin Design
(DBCD) procedure can be used to target any allocation proportion ρ. Throughout
this paper, we will use the DBCD procedure proposed by Hu and Zhang (2004)
g(α)(x, y) =

1 if x = 0
y( y
x
)α
y( y
x
)α+(1−y)( 1−y
1−x )
α
if 0 < x < 1
0 if x = 1
(3.2)
to skew the allocation at each randomization stage to target our optimal allocation
proportion. Here, α is a nonnegative number that controls the randomness of the
procedure. Then the probability of assign the (j + 1)th subject to treatment A is
g(nAj/j, ρˆj), where nAj/j is the observed proportion of subjects assigned to treatment
A so far, and ρˆj is the estimate of ρ in equation (3.1) after the j subjects. Hu and
Zhang (2004) have shown that both NA/n and ρˆ approach to the target allocation
proportion ρ as n increases.
For the above standard response adaptive randomization, the randomization pro-
cedure is solely based on the information from the primary endpoints. In that case,
this procedure will perform better when the primary endpoint can be observed im-
mediately relative to the enrollment period. In practice, however, one may need a
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relatively long time to obtain the primary outcome. When there are delayed primary
responses, less information will be available to skew the allocation.
3.2 Proposed method
Many clinical trials have surrogate endpoints that can by observed sooner than the
primary endpoint. These surrogate endpoints will provide additional information
about the primary endpoints which can be used in the randomization procedure. In
this section, we will propose a new response adaptive randomization design which
will extend the standard RAR to simultaneously account for the information from
the surrogate endpoint.
3.2.1 Likelihood distribution
Suppose Si and Ti are the surrogate and primary endpoints for the ith subject,
respectively. We assume that both the surrogate and primary endpoints have a
normal distribution. Specifically, we assume that Si and Ti follow a bivariate normal
distribution with mean vector µ and variance-covariance matrix ΣL. That is Si
Ti
 ∼ N2

 µS
µT
 ,
 σ2s σst
σst σ
2
t

 (3.3)
where
µ =
 µS
µT
 and ΣL =
 σ2s σst
σst σ
2
t
 .
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Based on the properties of the bivariate normal distribution, the conditional distri-
bution of primary endpoint given surrogate endpoint for subject i is also a normal
distribution:
Ti|Si = si ∼ N(µti|si , σ2t|s) (3.4)
where the conditional mean and variance can be expressed as:
µti|si = µT + σstσ
2
s(si − µS)
σ2t|s = σ
2
t − σ2stσ−2s
The contribution to the likelihood from subject i is the joint distribution of sur-
rogate and primary endpoint f(si, ti), which can be expressed as a product of two
parts: the marginal distribution of the surrogate endpoint f(si), and the condi-
tional distribution of primary endpoint given the surrogate endpoint f(ti|si). Let
D = (S1, · · · , Sn, T1, · · · , Tn) be the data that contains the surrogate and primary
endpoints, and ΘL = (µS, µT , σ
2
s , σ
2
t , σst) be the vector of unknown parameters, then
the likelihood for all the parameters in the model will be:
Ln(ΘL|D) =
n∏
i=1
f(si, ti) =
n∏
i=1
f(ti|si)f(si)
=
n∏
i=1
 1
2pi
√
σ2s
exp
{
−(si − µS)
2
2σ2s
}
× 1
2pi
√
σ2s|t
exp
{
−(ti − µti|si)
2
2σ2t|s
}
(3.5)
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3.2.2 Prior distribution
In this section, we will explore the use of conjugate priors for the purpose of obtaining
the posterior distribution of conditional mean and variance.
Normal-Inverse-Wishart Distribution
In probability theory and statistics, the Normal-inverse-Wishart(NIW) distribution
is a multivariate four-parameter family of continuous probability distributions. It is
the conjugate prior of a multivariate normal distribution with unknown mean and
unknown variance-covariance matrix[Murphy, 2007]. In our study, we assume that
the joint prior distribution of mean vector µ and variance-covariance matrix ΣL is a
Normal-inverse-Wishart distribution, such that (µ,ΣL) ∼ NIW (µ0, κ0, R, υ). Under
the above prior assumption, the prior distribution of mean µ is dependent on the
prior of variance-covariance matrix ΣL. Specifically, this prior distribution can be
expressed as below:
µ|ΣL ∼ N(µ0,ΣL/κ0)
ΣL ∼ IW (R, υ)
where µ0 is a parameter vector, κ0 is the sample size that the prior belief about µ is
equivalent to, R is a parameter matrix, and υ is the degrees of freedom.
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Then the prior distribution of (µ,ΣL) can be expressed as
p(µ,ΣL) = p(µ|ΣL)p(ΣL) = N2(µ0,ΣL/κ0)IW (R, υ)
=
|R|υ2
2
υp
2 Γ(υ
2
)
(
2pi
κ0
)− p
2
|ΣL|−
υ+p
2
−1 exp
{
−1
2
tr(RΣ−1L )−
κ0
2
(µ− µ0)′Σ−1L (µ− µ0)
}
∝ |ΣL|−
υ+p
2
−1 exp
{
−1
2
tr(RΣ−1L )−
κ0
2
(µ− µ0)′Σ−1L (µ− µ0)
}
(3.6)
where p is the rank of ΣL and p = 2 in this case.
Partitioning the Inverse-Wishart Distribution
As we mentioned in the previous section, the likelihood function is expressed as a
product of the marginal density of surrogate endpoint and the conditional density
of the primary endpoint given the surrogate endpoint. In consequence, the prior
distribution on ΣL needs to be partitioned, since the prior distributions should be
placed on parameters σ2s and σ
2
t|s[Shi, 2007]. The partitioning can be achieved by
applying the normal theory laid out by Dreze and Richard[Dreze and Richard, 1983].
Suppose the p×p random matrix Σ ∈ Cp has an Inverse-Wishart distribution, where
Cp denotes the set of p×p symmetric positive definite matrices. Specifically, suppose
Σ ∼ IW (R, υ), where R is a p× p matrix and υ is the degree of freedom. The first
moment of this density function is
E(Σ) =
1
υ − p− 1R (υ > p+ 1).
28
If both Σ and R can be partitioned as
Σ =
Σ11 Σ12
Σ21 Σ22
 , R =
R11 R12
R21 R22

where Σ11 and R11 are p1× p1, Σ22 and R22 are p2× p2, Σ12 and R12 are p1× p2, and
Σ21 and R21 are p2 × p1 matrices. Furthermore, if we define
Σ22.1 = Σ22 − Σ21Σ−111 Σ12 Ω = Σ−111 Σ12
R22.1 = R22 −R21R−111 R12 Ω˜ = R−111 R12
Then we will have
p(Σ11,Ω,Σ22.1) = p(Σ11)p(Ω|Σ22.1)p(Σ22.1) (3.7)
with
Σ11 ∼ IWp1×p1(R11, υ − p2) (3.8a)
Ω|Σ22.1 ∼MNp1×p2(Ω˜,Σ22.1 ⊗R−111 ) (3.8b)
Σ22.1 ∼ IWp2×p2(R22.1, υ) (3.8c)
The Ω|Σ22.1 in equation (3.8b) is a random matrix rather that a vector, and MN is
the matrix normal distribution which is the generalization of the multivariate normal
distribution.
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Partitioning the Inverse-Wishart prior on ΣL
In this chapter, since we only consider one surrogate endpoint, the variance-covariance
matrix ΣL is a 2× 2 matrix. The following partitioning on both random matrix ΣL
and parameter matrix R are considered:
ΣL =
σ2s σst
σst σ
2
t
 R =
r2s rst
rst r
2
t

where σ2s , σst, σ
2
t , r
2
s , rst, and r
2
t are all scalars. Therefore, the Inverse-Wishart prior
distribution for ΣL can be partitioned into the following three parts:
σ2s ∼ IW1×1(r2s , υ − 1) (3.9a)
Ωst|σ2t|s ∼MN1×1(Ω˜st, σ2t|s ⊗ r−2s ) (3.9b)
σ2t|s ∼ IW1×1(r2t|s, υ) (3.9c)
where
σ2t|s = σ
2
t − σ2stσ−2s Ωst = σ−2s σst
r2t|s = r
2
t − r2str−2s Ω˜st = r−2s rst
The Inverse-Wishart distributions for σ2s in equation (3.9a) and σ
2
t|s in equa-
tion (3.9c) are one-dimensional. The matrix normal distribution in equation (3.9b)
is one-dimensional as well. Since the univariate special case of the Inverse-Wishart
distribution is the Inverse-Gamma distribution, and the one-dimensional matrix nor-
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mal distribution will reduce to univariate normal distribution, the partition of the
Inverse-Wishart prior distribution for ΣL can be rewritten as
σ2s ∼ IG(
υ − 1
2
,
r2s
2
) (3.10a)
Ωst|σ2t|s ∼ N(Ω˜st, σ2t|sr−2s ) (3.10b)
σ2t|s ∼ IG(
υ
2
,
r2t|s
2
) (3.10c)
3.2.3 Estimation rule for allocation rate
In our proposed algorithm, we will use the conditional mean and conditional variance
of primary endpoint given surrogate endpoint for each treatment group to update
the allocation proportion for the next subject. To make inferences for the unknown
parameters, a Bayesian approach will be introduced. The Bayesian approach can
be used to estimate the entire posterior distribution, and there is no requirement
for the sample size. The Markov chain Monte Carlo (MCMC) method is a general
simulation method for sampling from posterior distributions and computing posterior
quantities of interest. It provides a convenient computation approach to fitting a
Bayesian model of a bivariate normal distribution. Thus, we will use the MCMC
method to fit our bivariate normal distribution model.
Suppose there are two treatment groups: A and B. Let µA = (µS,A, µT,A)
′ be the
mean vector for treatment A, where µS,A and µT,A are the means of the surrogate and
primary endpoint for treatment A, respectively. Similarly, µB = (µS,B, µT,B)
′ is the
mean vector for treatment B. ΣA is the variance-covariance matrix for treatment
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A and ΣB is for treatment B, where the two variance-covariance matrices can be
expressed as below:
ΣA =
σ2s,A σst,A
σst,A σ
2
t,A
 ΣB =
σ2s,B σst,B
σst,B σ
2
t,B

Suppose that the variance-covariance matrix for each treatment group has a Normal-
Inverse-Wishart prior as described in section 3.2.2, such that (µA,ΣA) ∼ NIW (µ0, κ0, R, υ)
and (µB,ΣB) ∼ NIW (µ0, κ0, R, υ). Furthermore, the variance-covariance matrices
ΣA and ΣB and the parameter matrix R will be partitioned as described in section
3.2.2, such that:
σ2s,A ∼ IG(
υ − 1
2
,
r2s
2
), σ2s,B ∼ IG(
υ − 1
2
,
r2s
2
)
Ωst,A|σ2t|s,A ∼ N(Ω˜st, σ2t|s,Ar−2s ), Ωst,B|σ2t|s,B ∼ N(Ω˜st, σ2t|s,Br−2s )
σ2t|s,A ∼ IG(
υ
2
,
r2t|s
2
), σ2t|s,B ∼ IG(
υ
2
,
r2t|s
2
)
where
Ωst,A = σ
−2
s,Aσst,A, Ωst,B = σ
−2
s,Bσst,B
Suppose Ti and Si are the primary and surrogate endpoints for subject i, respec-
tively. Let Zi denote the treatment indicator for the ith subject, where Zi = 1 if
subject i is in treatment A and Zi = 0 if in treatment B. Before assigning the ith
subject, we can get the Bayes estimator of µA = (µS,A, µT,A)
′, µB = (µS,B, µT,B)′,
σ2s,A, σ
2
s,B, Ωst,A, Ωst,B, σ
2
t|s,A, σ
2
t|s,B, which will be denote as µ˜A = (µ˜S,A, µ˜T,A)
′,
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µ˜B = (µ˜S,B, µ˜T,B)
′, σ˜2s,A, σ˜
2
s,B, Ω˜st,A, Ω˜st,B, σ˜
2
t|s,A, σ˜
2
t|s,B, respectively. Besides, the
following information can be obtained from the first i− 1 subjects:
nA,i =
i−1∑
k
Zk, nB,i =
i−1∑
k
(1− Zk)
SA,i =
i−1∑
k
SkZk, SB,i =
i−1∑
k
Sk(1− Zk)
The above information will be used in the allocation procedure.
3.2.4 Algorithm of the design
The proposed algorithm for response adaptive randomization for clinical trials with
normally distributed primary outcome is described below:
S1. Use the equal allocation randomization procedure for a certain number of sub-
jects at the beginning of the trial. Equal randomization is a useful way to
obtain initial parameter estimates that are required in a sequential estimation
procedure, such as the doubly adaptive biased coin design (DBCD) procedure.
As recommended by Nowachi et al., the number of subjects that are equally
allocated to treatment A and treatment B in the beginning are typically cho-
sen as 5% − 10% of the total sample size[Nowacki et al., 2015]. Suppose 2m0
subjects are equally assigned to each treatment groups, where 2m0 was chosen
as 10% of the total sample size.
S2. Before allocating the ith subject, update the following information based on
the first i− 1 subjects:
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nA,i : current total number of subjects assigned to treatment A;
nB,i : current total number of subjects assigned to treatment B;
S¯A,i =
1
nA,i
SA,i : mean of surrogate response assigned to treatment A so far;
S¯B,i =
1
nB,i
SB,i : mean of surrogate response assigned to treatment B so far;
S3. Calculate the Bayes estimators of conditional mean and variance of primary
endpoint given surrogate endpoint for each treatment group through a Bayesian
model based on the accumulated data:
σ˜2t|s,A : estimate of conditional variance of primary endpoint given surrogate
endpoint for treatment A;
σ˜2t|s,B : estimate of conditional variance of primary endpoint given surrogate
endpoint for treatment B;
µ˜t|s,A = µ˜t,A + Ω˜st,A(S¯A,i − µ˜s,A) : estimate of conditional mean of primary
endpoint given surrogate endpoint for treatment A;
µ˜t|s,B = µ˜t,B + Ω˜st,B(S¯B,i − µ˜s,B) : estimate of conditional mean of primary
endpoint given surrogate endpoint for treatment B;
S4. Calculate the current observed allocation proportion for treatment A and the
current target allocation proportion for treatment A:
rA,i =
nA,i
nA,i+nB,i
: current observed proportion of subjects assigned to treatment
A;
ρˆ =
√
µ˜t|s,B σ˜2t|s,A√
µ˜t|s,B σ˜2t|s,A+
√
µ˜t|s,Aσ˜2t|s,B
: current estimate of target allocation proportion
to treatment A.
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S5. Apply both the current observed treatment A allocation proportion and the
current treatment A target allocation proportion calculated in the previous step
to the DBCD procedure to calculate the treatment A allocation probability for
the ith subject:
Prob(TrtA) =
ρˆ( ρˆ
rA,i
)α
ρˆ( ρˆ
rA,i
)α + (1− ρˆ)( 1−ρˆ
1−rA,i )
α
where α is a nonnegative number that reflects the desired degree of random-
ization.
S6. Randomize the next subject using this treatment A allocation probability
Prob(TrtA).
S7. Repeat steps 2 - 6 until reaching the predetermined sample size.
3.3 Simulation study
3.3.1 Simulation targets
In this section, some simulation studies will be conducted to investigate the perfor-
mance of our proposed response adaptive randomization (RAR) for clinical trials with
normally distributed primary endpoint and correlated normally distributed surrogate
endpoint under different clinical scenarios. Specifically, our proposed algorithm will
be compared with equal randomization and standard RAR proposed by Zhang and
Rosenberger in 2006 (when only the primary endpoint was considered in the ran-
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domization procedure). There are two criteria that can be used to evaluate the
performance of response-adaptive randomization procedure[Zhang and Rosenberger,
2006]. One is the total expected response of the primary endpoint which will rep-
resent the ethical constraints. The procedure that gives the smallest total expected
response will be the most ”ethical” procedure. The other criteria that can be used is
the power of the test. In our simulation study, we are interested in: 1) how different
correlation between primary and surrogate endpoints affect the simulation results,
in terms of power, allocation proportions, number of subjects assigned to each treat-
ment group, and total expected response of the primary endpoint; 2) the effect of
delay in the primary endpoint; 3) how different sample sizes affect the simulation
results.
3.3.2 Sampling method
To make the three allocation procedures (equal randomization, standard RAR, and
proposed RAR) comparable, the total sample size will be calculated based on the two-
sided two-sample Welch’s t-test (unequal variance t-test) when we wish to have equal
sample sizes in each treatment groups. More specifically, the sample size is selected to
yield a 80% power at significance level of 0.05. The correlated primary and surrogate
endpoints are sampled from a bivariate normal distribution. As recommended by
Hu and Zhang,the exponential distributions are used for both the delay times of
primary endpoint for the two treatment groups and the subject entry time [Hu et al.,
2008]. The Gelman-Rubin diagnostic will be used as a numerical support to monitor
the convergence of iterative simulations. This approach is, for each parameter of
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interest, to compute the variance of the simulations from each chain, to average
these within-chain variances, and compare this to the variances of all the chains
mixed together [Gelman et al., 2011]. Basically, Gelman-Rubin measures whether
there is a significant difference between the variance within several chains and the
variance between several chains by a value that is called “scale reduction factors”.
3.3.3 Simulation settings
The correlated surrogate and primary endpoints for each treatment groups were
generated from the bivariate normal distribution:
 SA
TA
 ∼ N2 (µA,ΣA) ,
 SB
TB
 ∼ N2 (µB,ΣB)
where
µA =
 µs,A
µt,A
 , ΣA =
 σ2s,A σst,A
σst,A σ
2
t,A

and
µB =
 µs,B
µt,B
 , ΣB =
 σ2s,B σst,B
σst,B σ
2
t,B

The correlation between surrogate and primary endpoint will be denoted as ρst,A
and ρst,B, which can be calculated from the variance-covariance matrix. In our
simulation study, suppose there is a positive correlation between the surrogate and
primary endpoints, and the correlation for each treatment group is the same, which
is ρst,A = ρst,B = ρs,t. We are going to consider three different strengths for this
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relationship: low correlation(0.3 ≤ ρs,t < 0.5), moderate correlation(0.5 ≤ ρs,t <
0.7), and high correlation(0.7 ≤ ρs,t < 0.9). Table 3.1 below shows the possible
values of the parameters that we are going to use to generate the data.
Table 3.1: Parameters in the bivariate normal distribution model
Parameters Values
(µs,A, µs,B) (20, 24)
(µt,A, µt,B) (12.5, 15) (13, 15) (13.5, 15) (14, 15)
(σs,A, σs,B) (4, 3)
(σt,A, σt,B) (4, 2.5) (2.5, 4)
ρs,t 0.35 0.6 0.85
As mentioned in section 3.3.2 , the exponential distributions were used for the
delay times and subject entry times. Suppose the mean parameters of the delay
times of primary endpoint for treatment A and B are λ1 and λ2, respectively, and
the mean parameter for the subject entry times for both treatment groups is λ3. We
are going to consider two different delay scenarios. The first one corresponds to a
case where there are similar but moderate delay times for the primary responses of
the two treatment groups, such that (λ1, λ2, λ3) = (1, 1, 1). And then we considered
(λ1, λ2, λ3) = (10, 10, 1), which represents a large but identical delay times for both
treatment groups. Table 3.2 lists the different experimental scenarios of our simula-
tion study. Here, treatment B was considered as the control group and we assume
that treatment A always performs better than treatment B since a smaller response
is desirable. Scenarios Ia-Ig correspond to a situation when there is a weak correla-
tion between the surrogate and primary endpoints; scenarios IIa-IIe correspond to
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a moderate correlation; and scenarios IIIa-IIIe correspond to a strong correlation
between the surrogate and primary endpoints.
Normal-Inverse-Wishart prior distribution was placed on (µA,ΣA) and (µB,ΣB),
respectively. Conditional on the variance-covariance matrix, the mean vector has
a bivariate normal distribution, such that: µA|ΣA ∼ N2(µ0,ΣA/κ0), and µB|ΣB ∼
N2(µ0,ΣB/κ0). We take the prior expectations of µA and µB to be both a vector of
0’s, but with very large standard deviations. We also consider a weak prior distribu-
tion on the variance-covariance matrices ΣA and ΣB. Specifically, the following prior
parameters are used:
µ0 =
 0
0
 , R =
 1 0
0 1
 , κ0 = 0.001, υ = 4
For standard response adaptive randomization procedure, the maximum likeli-
hood estimators were used to calculate the allocation ratio. For the double adaptive
biased coin design (DBCD) (3.2), α = 2 was used, as suggested by Rosenberger and
Hu[Rosenberger and Lachin, 2004]. They found that such a choice of α provides a
reasonable trade-off between the randomness and optimality. 5, 000 simulations per
scenario was used to evaluate the performance of the proposed response adaptive
randomization. To assess the Markov Chain convergence, 3 chains with dispersed
initial values were used in each simulation to test whether they all converge to the
same target distribution.
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3.3.4 Results
To investigate the performance of our proposed response adaptive randomization
(proposed RAR) algorithm, the power, allocation proportions to the better treat-
ment group (treatment A), number of subjects assigned to better treatment group
(treatment A), and total expected response from all subjects under the proposed
allocation algorithm are compared with these under the equal allocation, and the
standard response adaptive randomization.
Table 3.7 shows a comparison of equal allocation randomization, standard re-
sponse adaptive randomization (standard RAR), and proposed response adaptive
randomization (proposed RAR) in terms of power for the two-sided two-sample t-
test. Both the standard RAR and proposed RAR yield a larger power compared
to equal allocation randomization, which is consistent with the conclusion made by
Rosenberger and Hu that the doubly-adaptive biased coin design was as powerful
or slightly more powerful than the equal allocation procedure [Rosenberger and Hu,
2004]. The power under the proposed RAR algorithm is similar to that under the
standard RAR, and it is neither influenced by the delay times in the primary end-
point, nor by the correlation between the primary and surrogate endpoints.
Table 3.8 shows the comparison of the three randomization procedures in terms
of the number of subjects assigned to treatment A, along with their standard devi-
ations. As we can see from the table, except for scenarios Ib, IIb, and IIIb, both
the standard RAR and proposed RAR assign more subjects to the better treatment
group than the equal allocation randomization procedure; compared to the standard
RAR, the proposed RAR tends to assign slightly more subjects to treatment A (the
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proposed algorithm assigns, on average, 1 to 2 more subjects to the better treatment
group, compared with the standard RAR procedure). For scenarios Ib, IIb, and
IIIb, where µT,A < µT,B, and σt,A < σt,B, the target allocation ratio calculated based
on ρ =
√
µT,Bσt,A√
µT,Bσt,A+
√
µT,Aσt,B
is less than 1/2, however, it is inappropriate to allocate
more subjects to the inferior treatment group (treatment B), thus the number of
subjects assigned to the better treatment group under both the standard RAR and
proposed RAR are the same as equal allocation randomization. Since the equal al-
location algorithm does not use the responses during the randomization procedure,
its performance is not affected as the delay in the primary endpoint increases. Even
the benefit of the standard RAR in terms of assigning more subjects to the better
treatment group does not change as the delay increases, the standard deviations of
number of subjects assigned to treatment A are getting larger when there is a larger
delay in the primary endpoint. The proposed RAR algorithm maintains the ben-
efit of assigning more subjects to the better treatment group, and is not sensitive
when the delay times increase. When there is a higher correlation between the surro-
gate and primary endpoint, the proposed algorithm has a similar or slightly smaller
standard deviations of the number of subjects assigned to treatment A.
Table 3.9 shows the observed allocation proportion with standard deviations for
the three randomization procedures. As expected, except for scenarios Ib, IIb, and
IIIb, both the standard RAR and proposed RAR allocate more than 50% subjects to
the better treatment group A. For different delay times in the primary endpoint, the
observed allocation proportions under the proposed RAR are similar. The variability
in the allocation proportions under the proposed RAR algorithm changes when we
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change the correlation between the primary and surrogate endpoints. Specifically,
the standard deviation is getting slightly larger when we decrease the correlation
between the surrogate and primary endpoints.
Table 3.10 shows the total responses with their standard deviations for the
three randomization procedures. Our proposed algorithm results in a comparable
or slightly reduction of the total observed responses.
Figure 3.1 and 3.2 compare the performance of the standard RAR and the pro-
posed RAR algorithm with regard to the treatment allocation under different delay
parameters. The mean and standard deviation are presented in those figures. In
figure 3.1 when the delay parameters are (λ1, λ2, λ3) = (10, 10, 1), the propose RAR
algorithm seems to have a smaller variability and stabilize a little bit quicker than the
standard RAR, even through the difference is not that huge. In Figure 3.2 when there
is a relatively large delay in the primary endpoint where (λ1, λ2, λ3) = (80, 80, 1),
we can see that our proposed algorithm reduces the variability and stabilizes much
quicker than the standard RAR.
3.4 Discussion
The standard response adaptive randomization procedures, which solely depend on
the primary endpoint, are affected by the delays in obtaining the primary outcome
measures. When there is a relatively long lag time to observe the primary end-
point, the benefit of standard RAR disappears since few outcome can be used to
skew the allocation probability. The proposed algorithm accounts for the informa-
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tion from the surrogate endpoint in the randomization procedure. Instead of only
using the primary endpoint, the proposed RAR algorithm simultaneously accounts
for the surrogate endpoint. Thus, more information will be used to skew the allo-
cation proportion to assign more subjects to the better treatment group under the
proposed method. The proposed algorithm results in more subjects in the superior
treatment group, while comparable to the standard response adaptive randomiza-
tion procedures. Under the proposed algorithm, the strength of correlation between
the primary and surrogate endpoints does not influence the power and the alloca-
tion proportion, but do affect the variability of allocation proportion to the better
treatment group.
However, there are some limitations of the proposed algorithm. First, this ap-
proach assumes that the surrogate endpoint can be observed immediately after the
treatment, which is not always the case. Second, the proposed method we discussed
so far only consider one surrogate endpoint. When there are multiple surrogates
available, it would be better if we can use those information in the randomization
procedure. If all the surrogate endpoints are normally distributed, then we can easily
extend the proposed response adaptive randomization from one surrogate endpoint
to a multiple surrogate version. Third, the proposed algorithm is only suitable when
both the surrogate and primary endpoints are normally distributed. We will consider
other distributions of surrogate and primary endpoints in the later chapters.
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N = 160. Simulations = 100.
ρst = 0.85, µT,A = 13.5, σt,A = 2.5, µT,B = 15, σt,B = 4, µS,A = 20, σs,A = 4, µS,B = 25, σs,B = 3.
The first 20 subjects were randomized using equal allocation randomization.
Figure 3.1: Comparison of the variation of the standard RAR method and proposed RAR
algorithm for handling delayed primary outcomes with (λ1, λ2, λ3) = (10, 10, 1).
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N = 160. Simulations = 100.
ρst = 0.85, µT,A = 13.5, σt,A = 2.5, µT,B = 15, σt,B = 4, µS,A = 20, σs,A = 4, µS,B = 25, σs,B = 3.
The first 20 subjects were randomized using equal allocation randomization.
Figure 3.2: Comparison of the variation of the standard RAR method and proposed RAR
algorithm for handling delayed primary outcomes with (λ1, λ2, λ3) = (80, 80, 1).
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Table 3.2: Parameter setup for different experimental scenario
Scenario N (λ1, λ2, λ3) ρst
Treatment A Treatment B
(µT,A, σt,A) (µS,A, σs,A) (µT,B, σt,B) (µS,B, σs,B)
Ia 90 (10, 10, 1) 0.35 (13, 4) (20, 4) (15, 2.5) (24, 3)
Ib 90 (10, 10, 1) 0.35 (13, 2.5) (20, 4) (15, 4) (24, 3)
Ic 90 (1, 1, 1) 0.35 (13, 4) (20, 4) (15, 2.5) (24, 3)
Id 160 (10, 10, 1) 0.35 (13.5, 4) (20, 4) (15, 2.5) (24, 3)
Ie 178 (10, 10, 1) 0.35 (12.5, 5.8) (20, 4) (15, 6) (24, 3)
If 350 (10, 10, 1) 0.35 (14, 4) (20, 4) (15, 2.5) (24, 3)
IIa 90 (10, 10, 1) 0.6 (13, 4) (20, 4) (15, 2.5) (24, 3)
IIb 90 (10, 10, 1) 0.6 (13, 2.5) (20, 4) (15, 4) (24, 3)
IIc 90 (1, 1, 1) 0.6 (13, 4) (20, 4) (15, 2.5) (24, 3)
IId 160 (10, 10, 1) 0.6 (13.5, 4) (20, 4) (15, 2.5) (24, 3)
IIe 178 (10, 10, 1) 0.6 (12.5, 5.8) (20, 4) (15, 6) (24, 3)
IIIa 90 (10, 10, 1) 0.85 (13, 4) (20, 4) (15, 2.5) (24, 3)
IIIb 90 (10, 10, 1) 0.85 (13, 2.5) (20, 4) (15, 4) (24, 3)
IIIc 90 (1, 1, 1) 0.85 (13, 4) (20, 4) (15, 2.5) (24, 3)
IIId 160 (10, 10, 1) 0.85 (13.5, 4) (20, 4) (15, 2.5) (24, 3)
IIIe 178 (10, 10, 1) 0.85 (12.5, 5.8) (20, 4) (15, 6) (24, 3)
IIIf 350 (10, 10, 1) 0.85 (14, 4) (20, 4) (15, 2.5) (24, 3)
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Table 3.3: Summary of power of the three randomization procedures using the two-sided
two-sample t-test
Scenario Sample size (N) Equal Allocation Standard RAR Proposed RAR
Ia 90 0.797 0.829 0.832
Ib 90 0.810 0.807 0.817
Ic 90 0.797 0.830 0.832
Id 160 0.802 0.825 0.836
Ie 178 0.801 0.812 0.801
If 350 0.801 0.816 0.821
IIa 90 0.795 0.835 0.828
IIb 90 0.806 0.806 0.817
IIc 90 0.795 0.837 0.832
IId 160 0.804 0.828 0.830
IIe 178 0.801 0.816 0.806
IIIa 90 0.798 0.839 0.830
IIIb 90 0.808 0.807 0.814
IIIc 90 0.798 0.839 0.828
IIId 160 0.802 0.828 0.826
IIIe 178 0.801 0.815 0.805
IIIf 350 0.798 0.821 0.816
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Table 3.4: Summary of average number of subjects assigned to treatmentA, with standard
deviations (SD) for the three randomization procedures
Scenario Sample size (N) Equal Allocation Standard RAR Proposed RAR
Ia 90 45 (4.80) 57 (5.06) 58 (5.46)
Ib 90 45 (4.79) 45 (2.64) 45 (2.51)
Ic 90 45 (4.80) 57 (4.65) 58 (5.12)
Id 160 80 (6.34) 100 (6.09) 102 (6.54)
Ie 178 89 (6.64) 93 (5.30) 93 (5.48)
If 350 175 (9.32) 218 (9.18) 219 (9.02)
IIa 90 45 (4.79) 57 (5.07) 58 (5.32)
IIb 90 45 (4.79) 45 (2.58) 45 (2.41)
IIc 90 45 (4.79) 57 (4.63) 58 (5.09)
IIc 160 80 (6.34) 100 (6.17) 101 (6.51)
IId 178 89 (6.64) 93 (5.29) 93 (5.37)
IIIa 90 45 (4.79) 57 (4.99) 58 (5.01)
IIIb 90 45 (4.80) 45 (2.62) 45 (2.30)
IIIc 90 45 (4.79) 57 (4.62) 58 (4.81)
IIId 160 80 (6.24) 100 (6.23) 101 (6.39)
IIIe 178 89 (6.64) 93 (5.28) 93 (5.45)
IIIf 350 175 (9.32) 218 (9.06) 219 (9.08)
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Table 3.5: Summary of observed allocation proportion of treatment A, with standard
deviations (SD) for the three randomization procedures
Scenario Sample size (N) Equal Allocation Standard RAR Proposed RAR
Ia 90 0.500 (0.0532) 0.634 (0.0562) 0.646 (0.0607)
Ib 90 0.500 (0.0532) 0.500 (0.0293) 0.501 (0.0279)
Ic 90 0.500 (0.0532) 0.633 (0.0517) 0.649 (0.0569)
Id 160 0.500 (0.0396) 0.627 (0.0381) 0.635 (0.0409)
Ie 178 0.500 (0.0373) 0.522 (0.0297) 0.525 (0.0308)
If 350 0.500 (0.0266) 0.622 (0.0262) 0.625 (0.0258)
IIa 90 0.500 (0.0533) 0.633 (0.0563) 0.645 (0.0592)
IIb 90 0.500 (0.0533) 0.500 (0.0287) 0.501 (0.0267)
IIc 90 0.500 (0.0533) 0.633 (0.0514) 0.647 (0.0565)
IIc 160 0.500 (0.0396) 0.627 (0.0386) 0.634 (0.0407)
IId 178 0.500 (0.0373) 0.522 (0.0297) 0.523 (0.0301)
IIIa 90 0.500 (0.0533) 0.633 (0.0555) 0.641 (0.0557)
IIIb 90 0.500 (0.0533) 0.500 (0.0291) 0.501 (0.0255)
IIIc 90 0.500 (0.0533) 0.633 (0.0513) 0.643 (0.0535)
IIId 160 0.500 (0.0396) 0.626 (0.0390) 0.633 (0.0399)
IIIe 178 0.500 (0.0373) 0.522 (0.0297) 0.524 (0.0306)
IIIf 350 0.500 (0.0266) 0.622 (0.0259) 0.624 (0.0260)
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Table 3.6: Summary of observed total responses, with standard deviations (SD) for the
three randomization procedures
Scenario Sample size (N) Equal Allocation Standard RAR Proposed RAR
Ia 90 1260 (33.47) 1236 (35.95) 1233 (36.30)
Ib 90 1260 (33.18) 1260 (32.16) 1261 (31.59)
Ic 90 1260 (33.47) 1235 (35.97) 1234 (35.46)
Id 160 2280 (44.04) 2250 (46.95) 2248 (46.30)
Ie 178 2448 (81.21) 2438 (79.61) 2437 (79.86)
If 350 5075 (63.38) 5032 (67.39) 5031 (67.40)
IIa 90 1260 (33.39) 1236 (36.15) 1234 (36.23)
IIb 90 1260 (33.17) 1260 (32.26) 1261 (31.75)
IIc 90 1260 (33.39) 1236 (35.78) 1234 (35.64)
IId 160 2280 (44.26) 2249 (46.77) 2248 (46.44)
IIe 178 2448 (81.20) 2438 (79.56) 2437 (79.66)
IIIa 90 1260 (33.28) 1235 (36.22) 1234 (36.10)
IIIb 90 1260 (33.10) 1260 (32.37) 1261 (31.80)
IIIc 90 1260 (33.28) 1235 (35.93) 1234 (35.36)
IIId 160 2280 (44.04) 2249 (46.82) 2249 (46.13)
IIIe 178 2448 (81.21) 2437 (79.79) 2437 (79.80)
IIIf 350 5075 (63.05) 5032 (66.39) 5032 (67.09)
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Table 3.7: Summary of power of the three randomization procedures using the two-sided
two-sample t-test
Scenario Sample size (N) Equal Allocation Standard RAR Proposed RAR
Id 160 0.802 0.833 0.834
Ie 178 0.801 0.812 0.803
If 350 0.801 0.816 0.816
IId 160 0.804 0.836 0.830
IIe 178 0.801 0.816 0.801
IIId 160 0.802 0.828 0.825
IIIe 178 0.801 0.815 0.804
IIIf 350 0.798 0.821 0.816
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Table 3.8: Summary of average number of subjects assigned to treatmentA, with standard
deviations (SD) for the three randomization procedures
Scenario Sample size (N) Equal Allocation Standard RAR Proposed RAR
Id 160 80 (6.34) 100 (6.04) 102 (6.48)
Ie 178 89 (6.64) 93 (5.30) 93 (5.48)
If 350 175 (9.32) 218 (9.18) 219 (9.10)
IIc 160 80 (6.34) 100 (6.09) 101 (6.46)
IId 178 89 (6.64) 93 (5.29) 93 (5.35)
IIId 160 80 (6.24) 100 (6.23) 101 (6.32)
IIIe 178 89 (6.64) 93 (5.28) 93 (5.46)
IIIf 350 175 (9.32) 218 (9.06) 219 (9.08)
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Table 3.9: Summary of observed allocation proportion of treatment A, with standard
deviations (SD) for the three randomization procedures
Scenario Sample size (N) Equal Allocation Standard RAR Proposed RAR
Id 160 0.500 (0.0396) 0.627 (0.0378) 0.634 (0.0405)
Ie 178 0.500 (0.0373) 0.522 (0.0297) 0.524 (0.0308)
If 350 0.500 (0.0266) 0.622 (0.0262) 0.624 (0.0260)
IIc 160 0.500 (0.0396) 0.627 (0.0381) 0.634 (0.0404)
IId 178 0.500 (0.0373) 0.522 (0.0297) 0.523 (0.0301)
IIId 160 0.500 (0.0396) 0.626 (0.0390) 0.633 (0.0394)
IIIe 178 0.500 (0.0373) 0.522 (0.0297) 0.524 (0.0307)
IIIf 350 0.500 (0.0266) 0.622 (0.0259) 0.624 (0.0260)
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Table 3.10: Summary of observed total responses, with standard deviations (SD) for the
three randomization procedures
Scenario Sample size (N) Equal Allocation Standard RAR Proposed RAR
Id 160 2280 (44.04) 2249 (46.38) 2248 (46.50)
Ie 178 2448 (81.21) 2438 (79.61) 2437 (80.15)
If 350 5075 (63.38) 5032 (67.39) 5032 (67.37)
IId 160 2280 (44.26) 2249 (46.32) 2248 (46.51)
IIe 178 2448 (81.20) 2438 (79.56) 2438 (79.83)
IIId 160 2280 (44.04) 2249 (46.82) 2248 (46.17)
IIIe 178 2448 (81.21) 2437 (79.79) 2437 (79.99)
IIIf 350 5075 (63.05) 5032 (66.39) 5032 (67.09)
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Chapter 4
Response Adaptive Design for
Clinical Trials with Time-to-Event
Outcomes using Surrogate
Endpoint
When the outcome of interest is time to event, the procedure used in the previous
chapter does not apply exactly. In this chapter, we are going to propose a response
adaptive randomization for clinical trials with survival outcomes, which will simul-
taneously account for the surrogate endpoint. Almost always, the survival outcomes
are delayed. As a result, we are not able to adapt the design. A surrogate, which
can be observed early, is expected to help in making the design adapt toward the
right direction. The exponential model is the most fundamental parametric model
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and is commonly used in survival analysis. Moreover, the exponential distribution
usually leads to closed form theoretical results [Zhang and Rosenberger, 2007]. Thus,
we will assume the primary time-to-event outcome has an exponential distribution
throughout this chapter.
4.1 RAR using primary outcome only
Consider a simple clinical trial with two treatment groups, Treatment A and Treat-
ment B. Let nA and nB be the number of patients in each treatment group, and
nA + nB = n. Suppose that the the primary endpoint of interest is time to event
outcome. Specifically, suppose Tik is the survival time for the ith patient in group
k, and follows an exponential distribution with mean θk, k = A,B. Furthermore,
assume that the survival times are subject to right censoring. Let Ci be the censor-
ing time for the ith patient, and is assumed to be independent of the survival time
Tik. Then for the ith patient in treatment k, tik = min(Tik, Ci) is the observed or
censored survival time with corresponding indicator variable δik, where δik = 1 if the
ith patient in treatment k is observed, and δik = 0 if that patient is censored.
As we mentioned in section 2.2, the general technique to obtain an optimal target
allocation is to solve the following optimization problem:

min
nA/nB
nAΨA + nBΨB
s.t.
σ2A
nA
+
σ2B
nB
≤ κ
(4.1)
where µk and σ
2
k, k = A,B, are the mean and finite variance of the primary response,
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and Ψk is a positive function of (µk, σk), which will be different for different goal of
the trial, and κ is a constant. Then the optimal allocation ratio would be
ρ =
σA
√
ΨB
σA
√
ΨB + σB
√
ΨA
(4.2)
Assume that k = E(δik) is the non-censoring proportion for patients in each
treatment group, and is fixed for patients in the same treatment group. Then un-
der the above setup, Zhang and Rosenberger (2007) proposed an optimal allocation
proportion by minimizing the total expected hazard [Zhang and Rosenberger, 2007].
The optimal allocation proportion can be obtained from equation (4.1) by taking
Ψk = θ
−1
k and σ
2
k =
θ2k
k
: 
min
nA/nB
nAθ
−1
A + nBθ
−1
B
s.t.
θ2A
nAA
+
θ2B
nBB
≤ κ
(4.3)
Solving the above optimization problem, we can get the optimal allocation proportion
of patients who are assigned to treatment A as
ρ =
√
θ3AB√
θ3AB +
√
θ3BA
(4.4)
The non-censoring proportion k will depend on the censoring scheme used in the
trial. In this chapter, we will introduce the censoring scheme proposed by Rosen-
berger and Seshaiyer (1997) and assume their censoring scheme throughout this
chapter [Rosenberger and Seshaiyer, 1997]. Suppose the trial has a duration D > 0,
and a recruitment period of length R > 0 and R < D. Patients enter the trial
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sequentially and patient arrival times are independent and follow an uniform distri-
bution on [0, R]. Meanwhile, the censoring time C is independent from the survival
time and is assumed to be uniformly distributed over [0, D]. Patients who do not
respond by the end of the trial are considered as administratively censored. Then
for the ith patient, we can observe tik = min(Tik, Ci, D − R) and δik = 1 if tik = Tik
and δik = 0 otherwise. Zhang and Rosenberger (2007) found that the non-censoring
proportion k = Pr(δik = 1) under the above censoring scheme has the following form
[Zhang and Rosenberger, 2007]
k = 1− θk
D
+ exp
(
−D
θk
)
θk
DR
{
exp
(
R
θk
)
(2θk −R)− 2θk
}
(4.5)
Under equation (4.5), Sverdlov et al. (2011) have shown that for fixed values of D
and R, the non-censoring proportion k is monotonically decreasing when the mean
parameter θk increases [Sverdlov et al., 2011]. This is easy to understand that the
longer the expected survival time, the less likely to observe an event (for example
death) before censoring, thus a smaller non-censoring proportion will be expected.
Then for the standard response adaptive randomization (RAR) where we only
consider the primary endpoint, the maximum likelihood estimator of the θk can be
obtained from the data and thus the optimal allocation proportion ρ can be estimated
every time before assigning the next patient.
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4.2 Proposed method
4.2.1 The finite mixture framework
A finite mixture model is a convex combination of two or more probability density
functions. It enriches the set of probability models by adding finite mixtures (or
weighted sums) of other standard distributions [Deb et al., 2008]. In general, the
density function of a m-component finite mixture is:
f(x) =
m∑
j=1
pjfj(x) (4.6)
where 0 < pj < 1 is weighting factor,
∑m
j=1 pj = 1, and fj(x) is the p.d.f. of the jth
component (e.g. Gaussian, Exponential, Weibull, etc).
In this chapter, we are going to consider a finite mixture of m exponential distri-
butions, which can also be called as a hyper-exponential distribution. Let X1, . . . , Xn
be a random sample from the hyper-exponential distribution, then the marginal dis-
tribution of X can be expressed as:
f(x) =
m∑
j=1
pj
1
θj
e
− x
θj (4.7)
The hyper-exponential cumulative distribution function for X, derived from equation
(4.7), is
F (x) =
m∑
j=1
pj(1− e−
x
θj ) (4.8)
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And the survival function for X, derived from (4.8), is
S(x) = 1− F (x) =
m∑
j=1
pje
− x
θj (4.9)
Then the expectation of X derived from hyper-exponential distribution in (4.7), can
be expressed as below:
E(X) =
m∑
j=1
pjθj (4.10)
4.2.2 Specifying the design parameters
Let nk be the number of subjects in treatment k, where k is the treatment indicator
and k = A or B. Suppose that there is a surrogate endpoint that has been validated
and this surrogate endpoint has m categories. Specifically, if the ith subject in treat-
ment k has a surrogate endpoint in the jth category, j = 1, 2, . . . ,m, then denote
this by Sk,j,i = 1 and Sk,r,i = 0 for 1 ≤ r ≤ m, r 6= j. Let Sk,i = (Sk,1,i, . . . , Sk,m,i) be
a vector, and we assume that the vectors are independent and identically distributed
across i = 1, . . . , nk, and each follows a multinomial distribution. Furthermore, sup-
pose the primary endpoint is a survival time that follows an exponential distribution,
and we denote Tk,i as the survival time for subject i in treatment k. Then condi-
tional on the surrogate endpoint being in the jth category, we assume Tk,i follows
an exponential distribution with mean parameter θk,j, j = 1, . . . ,m. Then under
the above assumptions, the primary endpoint Tk,i, i = 1, 2, . . . , nk, has a mixture of
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exponential distribution. The model can be presented as below:
k = A,B;
(Sk,1,i, Sk,2,i, . . . , Sk,m,i) ∼ Multi(1, pk,1, pk,2, . . . , pk,m);
Tk,i ∼
m∑
j=1
pk,jExp(θk,j)
(4.11)
where pk,j, j = 1, . . . ,m is the probability of a subject in treatment k having a
surrogate endpoint in the jth category, and
∑m
j=1 pk,j = 1, m ≥ 2. Based on the
model setup in (4.11), the marginal distribution of survival time (primary endpoint)
can be expressed as:
f(tk,i) =
m∑
j=1
pk,j
1
θk,j
e
− tk,i
θk,j (4.12)
The survival function for the primary endpoint given the surrogate endpoint can be
written as
S(tk,i) =
m∑
j=1
pk,je
− tk,i
θk,j (4.13)
The expectation of survival time for each group can be written as:
θk =
m∑
j=1
pk,jθk,j (4.14)
In this chapter, we are only going to consider the surrogate endpoint with two
categories, that is m = 2. So the mixture model will only have 2 components.
Suppose that associated with Tk,i, there is a censoring time Ci, and Ci is assumed to
be independent from Tk,i. Thus all subjects may have an event or be censored. Then
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for each subject, we will observe a pair of (tk,i, δk,i), where tk,i = min(Tk,i, Ci) is the
observed time and δk,i is an indicator if the event with δk,i = 1 if tk,i = Tk,i, and
δi = 0 if the ith subject in treatment k is censored. If we let φ = (θk,1, θk,2, pk,1, pk,2)
be a set of unknown parameters, then the likelihood function for the observed data
can be written as
L(φ|Data) =
B∏
k=A
nk∏
i=1
{f(tk,i)}δk,i {S(tk,i)}1−δk,i (4.15)
where f(ti) is the distribution of survival time for subject i as defined in equation
(4.12), and S(ti) is the corresponding survival function as equation (4.13).
4.3 Model fitting using MCMC
To make inference for the unknown parameters θk,j and pj, a Bayesian approach will
be introduced. Due to the complexity of the model, a Bayesian approach is deemed
to be appropriate. Posterior inference for mixture models can be performed via the
Markov Chain Monte Carlo simulation. Casella et al. (2002) mentioned that before
the Markov Chain Monte Carlo (MCMC) was introduced, there was no satisfactory
way to compute the Bayes estimators for mixture model [Casella et al., 2002, Marin
et al., 2005]. We are going to use the Gibbs sampler of Gelfand and Smith (1990) to
get the Bayes estimators of the unknown parameters.
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4.3.1 Label switching
Label-switching is a common issue in Bayesian estimation of mixture models. Con-
sider the mixture model in (4.12), where the mixture model has a finite number of
components (m). If the prior distributions on (θ1, . . . , θm) are exchangeable, then all
the marginals on the θj’s, j = 1, . . . ,m are identical, thus posterior distribution of
θj’s are invariant under permutations of the indices of the components. This means
that we cannot distinguish θ1 from θ2, θ1 from θ3, and so on, from the likelihood,
since they are exchangeable. This identifiability feature is crucial for both Bayesian
inference and computational issues [Marin et al., 2005].
There have been many suggestions as to how to deal with the label switching
problem. One solution is to use artificial identifiability constraints on the parameters
to break the symmetry in the likelihood [McLachlan and Peel, 2004]. For example,
if we go back to the mixture model in (4.12), a possible constraint is to order the
mean parameters, such that θ1 < θ2 < · · · < θm. This approach performs well when
the number of components is small. However, for a large number of components,
Celeux et al. pointed out that identifiability constraints have a consequence on the
posterior distributions, that it may lead to very poor estimates of the distribution in
the end. In that case, some other approach can be used to handle the label switching
issue, such as relabelling algorithms. We are not going to talk in detail of relabelling
algorithms in this chapter.
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4.3.2 Prior distribution
The Dirichlet distribution is a multivariate generalization of the beta distribution.
Similar to the beta distribution which can be used to measure the uncertainty about
two positive numbers that must sum to 1, the Dirichlet distribution can be used
to measure the uncertainty about m positive numbers that must sum to 1 [Es-
coto, 2013]. The Dirichlet distributions are commonly used as prior distributions
in Bayesian statistics. Moreover, just as the beta distribution is a conjugate prior
of the Bernoulli distribution, the Dirichlet distribution is the conjugate prior of the
categorical/ multinomial distribution.
In this chapter, we will consider the Dirichlet distribution as a prior for the
surrogate endpoint. Now go back to the mixture model in section (4.2.2), where
the surrogate endpoint follows a multinomial distribution, (Sk,1,i, Sk,2,i, . . . , Sk,m,i) ∼
Multi(1, pk,1, pk,2, . . . , pk,m) for k = A,B and i = 1, . . . , nk, where pk,j is the proba-
bility of a subject in treatment k has a surrogate endpoint in the jth category. Thus
in the Bayesian framework, we can assume that the vector of probability parame-
ters (pk,1, . . . , pk,m) has a Dirichlet prior with parameters (γk,1, . . . , γk,m), such that
(pk,1, . . . , pk,m) ∼ Dir(γk,1, . . . , γk,m). And the density function will be given by
pi(pk,1, . . . , pk,m|γk,1, . . . , γk,m) = 1
B(γk,1, . . . , γk,m)
m∏
j=1
p
γk,j−1
k,j
∝
m∏
j=1
p
γk,j−1
k,j
(4.16)
where B(γk,1, . . . , γk,m) =
∏m
j=1 Γ(γk,j)
Γ(
∑m
j=1 γk,j)
. If we let γk,0 =
∑m
j=1 γk,j, then the expectation
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of each probability parameter is equal to E[pk,j] =
γk,j
γk,0
. Moreover, γk,0 reflects the
uncertainty of the mixed exponential prior distribution. Specifically, the larger the
sum of the parameters γk,0, the more certain we are of the true weights (or probability
parameters) [Escoto, 2013].
The Gamma distribution is a conjugate prior to the exponential distributions.
However, as we mentioned in section (4.3.1), if we put an inverse gamma prior on each
of mean parameters (θk,1, . . . , θk,m), then their marginal distributions are identical,
and their posterior distributions are invariant. To solve the label switching problem,
a semi-conjugate prior will be chosen for the mean parameters (θk,1, . . . , θk,m), that
is put an identifiability constraint on θk,1, . . . , θk,m, such that θk,1 > θk,2 > . . . > θk,m.
Remember that we will only consider that the surrogate endpoint has 2 categories
(m = 2). Then the constraint will be θk,2 < θk,1. Furthermore, if we assume both
θk,1 and θk,2 have an Inverse-Gamma prior with parameter (αk,1, βk,1) and (αk,2, βk,2),
respectively, then the semi-conjugate prior for θk,1 and θk,2 can be written as
pi(θk,1, θk,2|αk,1, βk,1, αk,2, βk,2) = βk,1
Γ(αk,1)
θ
−αk,1−1
k,1 exp(−
βk,1
θk,1
)
× βk,2
Γ(αk,2)
θ
−αk,2−1
k,2 exp(−
βk,2
θk,2
)I(θk,2 < θk,1)
∝ θ−αk,1−1k,1 θ−αk,2−1k,2 exp(−
βk,1
θk,1
− βk,2
θk,2
)I(θk,2 < θk,1).
(4.17)
Combining the likelihood function in (4.15) and the above prior distributions
for (pk,1, pk,2) in (4.16) and (θk,1, θk,2) in (4.17), we will get the complete Bayesian
model and thus the posterior distribution of the set of unknown parameters φ =
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(θk,1, θk,2, pk,1, pk,2) given the data, which can be expressed as below:
pi(θk,1, θk,2, pk,1, pk,2) ∝ L(φ|Data)pi(pk,1, pk,2)pi(θk,1, θk,2) (4.18)
4.3.3 Estimation procedure
To calculate the allocation rate, we need to estimate the marginal mean survival time
for each treatment group. As we mentioned before, the unknown parameters will be
estimated through a Bayesian model. Specifically, we will use the Markov Chain
Monte Carlo (MCMC) methods through JAGS and R to fit our proposed model
and then obtain samples from the posterior distribution. JAGS (Just Another Gibbs
Sampler) is a well established statistical program for analysis of Bayesian hierarchical
models using Markov Chain Monte Carlo (MCMC) simulation [Plummer et al., 2003].
In section (4.2.2), we assume that the surrogate endpoint has a multinomial
distribution, and conditional on the surrogate endpoint being in the jth category,
the primary outcome Tk,i follows an exponential distribution with mean parameter
θk,j:
k = A,B;
(Sk,1,i, Sk,2,i, . . . , Sk,m,i) ∼ Multi(1, pk,1, pk,2, . . . , pk,m);
Tk,i ∼
m∑
j=1
pk,jExp(θk,j)
As we mentioned in section (4.3.2), a semi-conjugate prior was chosen for the mean
parameters (θk,1, . . . , θk,m) to solve the label switching problem. To make the model
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easily implemented in JAGS, we will re-write the prior for the mean parameters
(θk,1, θk,2) as below:
θk,2 ∼ IG(αk,2, βk,2);
∆k ∼ IG(αk,0, βk,0);
θk,1 = ∆k + θk,2.
(4.19)
This prior setup can make sure that we put an identifiability constraint on the mean
parameters, such that θk,1 > θk,2. Then the Bayesian model for our mixture of two
exponential distributions can be present below:
k = A,B;
(Sk,1,i, Sk,2,i) ∼ Multi(1, pk,1, pk,2), fori = 1, 2, . . . , nk;
Tk,i ∼
2∑
j=1
pk,jExp(θk,j);
(pk,1, pk,2) ∼ Dir(γk,1, γk,2);
θk,2 ∼ IG(αk,2, βk,2);
∆k ∼ IG(αk,0, βk,0);
θk,1 = ∆k + θk,2.
(4.20)
where Exp(·) is the exponential distribution, Dir(·) is the Dirichlet distribution, and
IG(·) is the inverse gamma distribution. Then we will use the JAGS to obtain
the posterior mean of unknown parameters pk,1, pk,2, θk,1, θk,2, and denote them as
p˜k,1, p˜k,2, θ˜k,1, θ˜k,2, respectively. Then, we will use equation (4.10) to estimate the
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mean survival time for each treatment group:
θ˜k = p˜k,1θ˜k,1 + p˜k,2θ˜k,2
and plug these estimates in equation (4.5) to get the estimate of the non-censoring
proportion:
˜k = 1− θ˜k
D
+ exp
(
−D
θ˜k
)
θ˜k
DR
{
exp
(
R
θ˜k
)
(2θ˜k −R)− 2θ˜k
}
4.4 Algorithm of the design
The proposed algorithm for response adaptive randomization for survival primary
outcomes is described below:
S1. To begin with the procedure, first an equal randomization with a prefixed
number of subjects 2m0 will be performed. Equal randomization is a useful
way to obtain initial parameter estimates that are required in a sequential
estimation procedure, such as the DBCD procedure. However, the prefixed
number os subjects in the equal randomization procedure is not clear and most
time is arbitrary without any statistical justification [Xu and Yin, 2014]. Xu
and Yin (2014) selected the number of subjects in the equal randomization
stage large enough to make sure there is a treatment difference before they
moved to the adaptive randomization. Nowacki et al. (2015) chose 5%− 10%
of the total sample size in the equal randomization procedure [Nowacki et al.,
2015].
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S2. Before allocating the ith subject, update the following information based on
the first i− 1 subjects:
nA,i : current total number of subjects assigned to treatment A;
nB,i : current total number of subjects assigned to treatment B.
S3. Calculate the Bayes estimators of the unknown parameters through the Bayesian
model based on the accumulate data:
θ˜A = p˜1,Aθ˜1,A + p˜2,Aθ˜2,A : posterior estimate of marginal mean survival time
for A;
θ˜B = p˜1,B θ˜1,B + p˜2,B θ˜2,B : posterior estimate of marginal mean survival time
for B;
˜A : estimate of non-censoring proportion for subjects in treatment A;
˜B : estimate of non-censoring proportion for subjects in treatment A.
S4. Calculate the current treatment A allocation proportion and the current treat-
ment A target allocation proportion:
rA,i =
nA,i
nA,i+nB,i
: current observed proportion of subjects assigned to treatment
A;
ρˆ =
√
θ˜3A˜B√
θ˜3A˜B+
√
θ˜3B ˜A
: current estimate of target allocation proportion to treat-
ment A.
S5. Apply both the current observed treatment A allocation proportion and the
current treatment A target allocation proportion calculated in the previous step
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to the DBCD procedure to calculate the treatment A allocation probability for
the ith subject:
Prob(TrtA) =
ρˆ( ρˆ
rA,i
)α
ρˆ( ρˆ
rA,i
)α + (1− ρˆ)( 1−ρˆ
1−rA,i )
α
where α is a nonnegative number that reflects the desired degree of random-
ization.
S6. Randomize the next subject using this treatment A allocation probability
Prob(TrtA).
S7. Repeat steps 2 - 6 until reaching the predetermined sample size.
4.5 Simulation study
4.5.1 Simulation targets
In this section, we will conduct a number of simulations to evaluate the performance
of our proposed response adaptive randomization for clinical trials with time-to-event
primary outcome and binary surrogate endpoint under different clinical scenarios.
Specifically, our proposed algorithm will be compared with two other randomization
procedures: (i) equal randomization procedure for which each subjects is assigned
to either treatment A or treatment B with probabilities (0.5, 0.5) and (ii) the stan-
dard response adaptive randomization for survival outcome proposed by Zhang and
Rosenberger in 2007, where the allocation proportion is updated solely based on the
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primary endpoint.
As recommended by Sverdlov et al. (2011), several characteristics will be com-
pared between the proposed algorithm and the other two randomization procedures
to evaluate the performance of the new randomization procedure: (1) simulated allo-
cation proportions: larger proportion of subjects are expected to be assigned to more
efficacious treatment group; (2) the power for testing equality of treatment effects:
the power under the proposed algorithm is expected to be at least as powerful as the
other two randomization procedure; (3) average number of patients on the superior
treatment group; (4) average number of events (deaths); and (5) total observed sur-
vival time [Sverdlov et al., 2011]. So in our simulation study, we are interested in: 1)
how different response rate in the surrogate endpoint affect the simulation results,
in terms of the five characteristics we talked before; 2) the effect of delay (censoring
proportion) in the primary endpoint; and 3) how different sample sizes affect the
simulation results.
4.5.2 Sampling method
For each clinical scenario, the sample size was chosen such that the equal random-
ization procedure has at least 80% power and 0.05 significance level of the two-sided
Wald test for testing H0 : θA = θB:
Z =
θˆA − θˆB√
θˆ2A/rA + θˆ
2
B/rB
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where θˆA and θˆB are the maximum likelihood estimators of mean survival time for
each treatment group, and rA and rB are the total number of failures for each treat-
ment group.
The surrogate endpoint was sampled from a two dimensional multinomial dis-
tribution (or equally the binomial distribution). And then the primary endpoint
was sampled from a mixture of two exponential distributions based on the sampled
surrogate endpoint. As we mentioned before, Rosenberger and Seshaiyer’s (1997)
censoring scheme will be assumed throughout this chapter. So for both treatment
A and treatment B, subject arrival time was generated from a uniform distribution
over [0, R], and the censoring time was sampled from a uniform distribution over
[0, D]. For convergence diagnostics, then Gelman-Rubin diagnostic was used as a
numerical support for the convergence of the chains. The Gelman-Rubin approach
is, for each parameter or quantity of interest, to compute the variance of the simu-
lations from each chain, to average these within-chain variances, and compare this
to the variances of all the chains mixed together [Gelman et al., 2011]. Basically,
Gelman-Rubin measures whether there is a significant difference between the vari-
ance within several chains and the variance between several chains by a value that
is called “scale reduction factors”.
4.5.3 Simulation settings
As in section 4.1, Rosenberger and Seshaiyer’s (1997) censoring scheme with recruit-
ment period R = 55 and duration D = 96 was considered. This setup was chosen to
match the experimental setting of a head and neck cancer trial reported by Fountzi-
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las et al. [Fountzilas et al., 2004]. And this setup was also commonly used in a
lot of simulation studies of response adaptive randomization for survival outcome.
The surrogate endpoint for each treatment group was generated from a multinomial
distribution Multi(1, pk,1, pk,2). Different combinations of the response rates of surro-
gate endpoint for each treatment group was considered. The primary survival time
was generated from the mixture of two exponential distributions. We will investi-
gate the performance of our proposed algorithm under different expected survival
times. Table 4.1 lists the different experimental scenario of our simulation study.
Treatment B was considered as the control group and we assume that treatment A
always performs better than treatment B. Furthermore, we assume that the mean
survival time for subjects having a surrogate endpoint in the first category is greater
than the mean survival time if having a surrogate endpoint in the second category.
Scenarios Ia-If correspond to a situation when subjects in treatment A have a higher
rate of having a surrogate endpoint in the first category than in treatment B, and
the mean survival time in treatment A is greater than that in treatment B. IIa-IIe
correspond to a situation when subjects in treatment A have the same rate of having
a surrogate endpoint in the first category as in treatment B, but treatment A has a
higher survival time compared to treatment B. And scenarios IIIa-IIIc correspond
to a situation when subjects in treatment A have a higher rate of having a surrogate
endpoint in the first category than in treatment B, but the mean survival times for
subjects having a surrogate endpoint in the jth category for both treatment groups
are the same. We should note that a larger expected survival times corresponds to
a situation when there is a larger proportion of censoring, which can also be consid-
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ered as a larger proportion of delays. Table 4.1 also lists the proportion of censoring
(or delay) for each treatment group under different clinical scenarios. For example,
under scenario Ia, the proportion of non-censoring for treatment A is 0.49, while
0.80 for treatment B. When the mean survival time for treatment A decreases, the
proportion of non-censoring decreases as well.
The Dirichlet distribution was considered as the prior distribution for the surro-
gate endpoint. For both treatment A and treatment B, we assume that (pk,1, pk,2) ∼
Dir(0.5, 0.5). So γk,0 = γk,1 + γk,2 = 1. Remember in section 4.3.2 we mentioned
that γk,0 reflects the uncertainty of the mixed exponential prior distribution, and the
larger the γk,0 is, the more certain we are of the true values of pk,1 and pk,2. So under
this parameterization for the Dirichlet distribution, we assume that there is a vague
information for the response rates of the surrogate endpoints.
The mean parameters θk,1, θk,2 have an inverse gamma prior. Remember in section
4.3.3 we mentioned that we will put the inverse gamma priors on θk,2 and ∆k where
∆k = θk,1 − θk,2, such that θk,2 ∼ IG(αk,2, βk,2),∆k ∼ IG(αk,0, βk,0), to solve the
label switching problem. In this simulation study, we assume that the expectations
of θk,2 and ∆k equal to their theoretical values for treatment B (control group), such
that θB,2 =
βk,2
αk,2−1 , and ∆B =
βk,0
αk,0−1 . So for scenarios Ia-If, IIa-IIc, and IIIa, we
assume θk,2 ∼ IG(11, 70) and ∆k ∼ IG(11, 280); for scenarios IId-IIe, and IIIb, we
assume θk,2 ∼ IG(11, 70) and ∆k ∼ IG(11, 170); and for scenarios IIIc, we assume
θk,2 ∼ IG(11, 90) and ∆k ∼ IG(11, 490). Under this parameterization, we assume
that the amount of information in these prior distributions is approximately equal
to that from 11 subjects. Furthermore, we assume that the information is from
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the historical data (or control group). This prior setup was chosen based on the
recommendation of Huang et al. (2009), where they explained their considerations
of choosing such a prior: the priors should be reasonably informative in order to
show the difference between response categories of surrogate endpoint, yet they are
not so strong that they can be altered by the data in the ongoing trial [Huang et al.,
2009]. Normally, under the inverse gamma prior distribution, for example IG(α, β),
if the investigators choose α/(α + β) to be small (say, less than or equal to 0.1),
then they wish to have a low prior weight on the historical data. And if they choose
α/(α+ β) to be greater than 0.5, then they want to have a large prior weight on the
historical data [Ibrahim et al., 2005]. In our simulation study, αk,0/(αk,0 + βk,0) for
all the scenarios are smaller than 0.1, and αk,2/(αk,2 + βk,2) is slightly larger than
0.1 (11/(11+70)=0.13, 11/(11+90)=0.11). These parameterizations reflect we put a
relatively low prior weight on the historical data.
As we mentioned before, the proposed algorithm will be compared with the stan-
dard response adaptive randomization, which does not use the information from the
surrogate endpoint. For the standard RAR, we assume that the survival times for
subjects in each treatment group have exponential distributions with mean param-
eters θA and θB, respectively. To estimate these unknown parameters, a Bayesian
approach will be used as well. Similar as what we did for our proposed algorithm, we
will put a vaguely informative prior on θA and θB, such that both θA and θB have an
inverse gamma prior as IG(α0, β0), and β0/(α0 − 1) = θB. So for scenarios Ia-If, we
assume θA, θB ∼ IG(11, 182); for scenarios IIa-Ic, we assume θA, θB ∼ IG(11, 294);
for scenarios IId-Ie, we assume θA, θB ∼ IG(11, 206); for scenario IIIa, we assume
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θA, θB ∼ IG(11, 121); for scenario IIb, we assume θA, θB ∼ IG(11, 154); and for sce-
nario IIIc, we assume θA, θB ∼ IG(11, 237). We will use the posterior means of θA
and θB to obtain the target allocation proportion for the standard RAR procedure.
For the DBCD procedure, α = 2 was chosen based on the recommendation of
Rosenberger and Hu (2004), who showed that such a choice of α provides a reasonable
trade-off between randomness and optimality [Rosenberger and Hu, 2004]. For each
randomization procedure, 10,000 simulations per scenario was performed to evaluate
the performance of our proposed algorithm. To assess the Markov Chain convergence,
3 chains with different set of initial values were used to test whether they all converge
to the same target distribution.
4.5.4 Results
To investigate the performance of our proposed response adaptive randomization
procedure (proposed RAR), we will compare the power, the observed allocation pro-
portion to treatment A, the average number of subjects in treatment A, the average
number of event, and the average total observed survival time under the proposed al-
gorithm with those under the equal allocation randomization and standard response
adaptive randomization.
Table 4.2 shows the comparison of the three randomization procedures in terms
of power for the Wald test. Except for scenarios Ie, If, and IIIc, both the standard re-
sponse adaptive randomization and our proposed adaptive randomization procedure
yield a larger power compared to equal allocation randomization. And for scenarios
Ie, If, and IIIc, the power under the proposed RAR algorithm is similar to that under
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the equal allocation randomization procedure. This is consistent with the conclusion
made by Zhang and Rosenberger that the power under the double-adaptive biased
coin design was as powerful or slightly more powerful than the equal randomization
procedure [Rosenberger and Hu, 2004]. Moreover, the power under our proposed
RAR algorithm is comparable as that under the standard RAR procedure.
Table 4.3 shows the average number of subjects assigned to treatment A, along
with their standard deviations. From table 4.3, one can see that both the standard
response adaptive randomization and our proposed response adaptive randomization
are more ethical than the equal allocation randomization procedure, since both of
them assigned more subjects to treatment A (the group that has a larger mean
survival time), as compared to the equal allocation. Meanwhile, except for scenarios
IId and IIe where the number of subjects assigned to treatment A are the same for
standard and proposed RAR, our proposed algorithm tends to allocate slightly more
subjects to treatment A as compared to the standard RAR. On average, our proposed
algorithm assigns 1 to 5 more subjects to the better treatment group, compared with
the standard RAR procedure.
Table 4.4 shows the observed allocation proportion to treatment A, along with
their standard deviations. As expected, both the standard response adaptive ran-
domization and the proposed adaptive randomization have an allocation proportion
to treatment A greater then 0.5. The allocation proportion under the proposed ran-
domization procedure is slightly greater than that under the standard RAR for all
the experimental scenarios. However, it can be seen from table 4.4 that our proposed
algorithm has higher standard deviations of allocation proportions than the standard
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RAR procedure. When there is a larger percentage of censoring, the difference of
observed allocation proportion between the standard and proposed RAR is larger as
well. For instance, when the proportion of censoring decreases (as in scenarios Ia-If
where the proportion of non-censoring in treatment A increases from 0.49 to 0.70),
the difference of observed allocation proportion to treatment A decreases from 0.024
to 0.002. Thus, the benefit of assigning more subjects to a better treatment under
our proposed algorithm is more obvious when there is a relatively large delay in the
primary outcome, as compared to the standard RAR procedure.
Table 4.5 and table 4.6 show the average number of events and the average total
observed survival time for each of the three randomization procedure, along with the
standard deviations, respectively. Both the standard response adaptive randomiza-
tion and our proposed adaptive randomization reduce the average number of events
(deaths) as compared to the equal allocation procedure. For all the experimental sce-
narios, 3-6 fewer events for both the standard RAR and proposed RAR as compared
to the equal allocation randomization. Compared with standard RAR procedure, our
proposed algorithm has a comparable or a slightly reduced number of events. On
average, our proposed algorithm has 1 fewer event than the standard RAR procedure
for scenarios Ib, Ic, IIIa, and IIIc, and a same number of events as standard RAR
for other scenarios. Even through these reductions is not huge, we still think any
reduction in the number of events is desirable in survival trials. Also, it is known that
in survival analysis, power is directly related to the number of events. Therefore, one
cannot expect a large reduction in the number of events without sacrificing the power
[Sverdlov et al., 2011]. In table 4.6, one can see that except for scenarios IIa-IIc, both
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the standard and proposed RAR have a relatively higher observed total survival time
than the equal allocation randomization procedure. For scenarios IIa-IIc, the equal
allocation procedure has a larger total observed survival time. That may because for
these three scenarios, the percentage of censoring is pretty large, thus at the end of
the trial, the number of subjects having an event that can be used in the analysis is
small. Our proposed algorithm remains a comparable total observed survival time
as the standard response adaptive randomization procedure.
4.6 Discussion
In this chapter, we proposed a new response adaptive randomization procedure for
clinical trials with survival primary endpoints. In clinical trials, especially for survival
trials, censoring is very common. At the meantime, surrogate endpoints can always
be obtained sooner than the primary survival time. When the surrogate endpoints
becomes available, we should not ignore those information. Thus, under our pro-
posed algorithm, we connect the surrogate endpoint with the primary survival time,
and use these information in the adaptive randomization procedure. Specifically,
we model the relationship between the surrogate and primary endpoint through a
mixture model (a mixture of exponential distributions), and estimate the parameters
of interest through a Bayesian approach. Through simulation studies, we find that
our proposed response adaptive randomization is more effective in assigning subjects
to better treatments as compared with equal allocation randomization and as effec-
tive as or even performs better than the standard response adaptive randomization
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procedure. Specifically, the proposed algorithm tends to allocate more subjects to
the better performance group, decreases the average number of events, and remains
a comparable power as compared to the standard response adaptive randomization
procedure.
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Table 4.1: Parameter setup for different experimental scenario
Scenario Sample Size
Treatment A Treatment B
(p1,A, p2,A) (θ1,A, θ2,A) A (p1,B, p2,B) (θ1,B, θ2,B) B
Ia 66 (0.7, 0.3) (76, 9) 0.49 (0.4, 0.6) (35, 7) 0.80
Ib 74 (0.7, 0.3) (68, 9) 0.53 (0.4, 0.6) (35, 7) 0.80
Ic 90 (0.7, 0.3) (58, 9) 0.57 (0.4, 0.6) (35, 7) 0.80
Id 134 (0.7, 0.3) (47, 9) 0.63 (0.4, 0.6) (35, 7) 0.80
Ie 182 (0.7, 0.3) (41, 8) 0.67 (0.4, 0.6) (35, 7) 0.80
If 246 (0.7, 0.3) (36, 8) 0.70 (0.4, 0.6) (35, 7) 0.80
IIa 150 (0.8, 0.2) (76, 9) 0.46 (0.8, 0.2) (35, 7) 0.69
IIb 192 (0.8, 0.2) (68, 9) 0.49 (0.8, 0.2) (35, 7) 0.69
IIc 302 (0.8, 0.2) (58, 9) 0.54 (0.8, 0.2) (35, 7) 0.69
IId 142 (0.8, 0.2) (48, 9) 0.60 (0.8, 0.2) (24, 7) 0.78
IIe 224 (0.8, 0.2) (41, 9) 0.64 (0.8, 0.2) (24, 7) 0.78
IIIa 132 (0.7, 0.3) (58, 9) 0.57 (0.3, 0.7) (58, 9) 0.74
IIIb 158 (0.7, 0.3) (35, 7) 0.71 (0.3, 0.7) (35, 7) 0.83
IIIc 226 (0.7, 0.3) (24, 7) 0.80 (0.3, 0.7) (24, 7) 0.97
81
Table 4.2: Summary of power of the three randomization procedures using the two-sided
Wald test
Scenario Sample size (N) Equal Allocation Standard RAR Proposed RAR
Ia 66 0.840 0.876 0.875
Ib 74 0.844 0.867 0.865
Ic 90 0.846 0.871 0.864
Id 134 0.871 0.881 0.871
Ie 182 0.862 0.869 0.861
If 246 0.843 0.844 0.842
IIa 150 0.826 0.844 0.844
IIb 192 0.832 0.846 0.846
IIc 302 0.832 0.837 0.840
IId 142 0.824 0.842 0.847
IIe 224 0.834 0.845 0.837
IIIa 132 0.849 0.849 0.860
IIIb 158 0.847 0.855 0.855
IIIc 226 0.849 0.848 0.846
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Table 4.3: Summary of average number of subjects assigned to treatmentA, with standard
deviations (SD) for the three randomization procedures
Scenario Sample size (N) Equal Allocation Standard RAR Proposed RAR
Ia 66 33 (4.05) 47 (4.63) 49 (5.12)
Ib 74 37 (4.30) 53 (5.21) 55 (5.63)
Ic 90 45 (4.78) 64 (6.24) 66 (6.78)
Id 134 67 (5.85) 94 (8.94) 96 (9.53)
Ie 182 91 (6.74) 124 (11.53) 126 (12.20)
If 246 123 (7.85) 162 (14.49) 163 (15.42)
IIa 150 75 (6.14) 102 (10.53) 104 (10.72)
IIb 192 96 (6.93) 128 (12.67) 131 (13.30)
IIc 302 151 (8.79) 195 (18.15) 199 (18.91)
IId 142 71 (5.99) 96 (9.68) 96 (9.56)
IIe 224 112 (7.51) 147 (13.68) 147 (13.53)
IIIa 132 66 (5.78) 91 (8.59) 96 (9.90)
IIIb 158 79 (6.30) 108 (10.36) 112 (10.47)
IIIc 226 113 (7.53) 149 (13.38) 151 (12.47)
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Table 4.4: Summary of observed allocation proportion to treatment A, with standard
deviations (SD) for the three randomization procedures
Scenario Sample size (N) Equal Allocation Standard RAR Proposed RAR
Ia 66 0.500 (0.0613) 0.715 (0.0702) 0.739 (0.0775)
Ib 74 0.500 (0.0581) 0.713 (0.0704) 0.738 (0.0760)
Ic 90 0.500 (0.0531) 0.709 (0.0693) 0.733 (0.0754)
Id 134 0.500 (0.0437) 0.699 (0.0667) 0.715 (0.0711)
Ie 182 0.500 (0.0370) 0.679 (0.0634) 0.690 (0.0670)
If 246 0.500 (0.0319) 0.660 (0.0589) 0.662 (0.0627)
IIa 150 0.500 (0.0409) 0.679 (0.0702) 0.693 (0.0714)
IIb 192 0.500 (0.0361) 0.668 (0.0660) 0.683 (0.0693)
IIc 302 0.500 (0.0291) 0.646 (0.0601) 0.660 (0.0626)
IId 142 0.500 (0.0422) 0.678 (0.0681) 0.676 (0.0673)
IIe 224 0.500 (0.0335) 0.656 (0.0611) 0.656 (0.0604)
IIIa 132 0.500 (0.0438) 0.691 (0.0650) 0.731 (0.0750)
IIIb 158 0.500 (0.0399) 0.684 (0.0656) 0.706 (0.0663)
IIIc 226 0.500 (0.0333) 0.658 (0.0592) 0.668 (0.0552)
84
Table 4.5: Summary of average number of events, with standard deviations (SD) for the
three randomization procedures
Scenario Sample size (N) Equal Allocation Standard RAR Proposed RAR
Ia 66 46 (3.73) 42 (4.10) 42 (4.15)
Ib 74 52 (3.87) 49 (4.36) 48 (4.34)
Ic 90 65 (4.22) 62 (4.70) 61 (4.77)
Id 134 100 (5.03) 96 (5.47) 96 (5.55)
Ie 182 139 (5.71) 135 (6.21) 135 (6.12)
If 246 191 (6.55) 187 (6.93) 187 (7.02)
IIa 150 93 (5.93) 88 (6.54) 88 (6.67)
IIb 192 121 (6.63) 116 (7.31) 116 (7.34)
IIc 302 197 (8.32) 191 (8.91) 191 (8.91)
IId 142 101 (5.36) 97 (9.68) 97 (5.91)
IIe 224 164 (6.68) 160 (7.08) 160 (7.11)
IIIa 132 94 (5.19) 90 (5.62) 89 (5.78)
IIIb 158 125 (5.08) 122 (5.49) 122 (5.45)
IIIc 226 190 (5.47) 188 (5.81) 187 (5.83)
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Table 4.6: Summary of total observed survival time, with standard deviations (SD) for
the three randomization procedures
Scenario Sample size (N) Equal Allocation Standard RAR Proposed RAR
Ia 66 627 (117.75) 642 (123.25) 640 (122.61)
Ib 74 717 (124.02) 738 (133.29) 739 (130.56)
Ic 90 892 (138.67) 926 (145.05) 932 (146.02)
Id 134 1358 (167.82) 1420 (176.44) 1427 (178.78)
Ie 182 1842 (192.62) 1917 (199.46) 1925 (201.80)
If 246 2494 (220.70) 2598 (231.26) 2595 (228.77)
IIa 150 1676 (203.16) 1635 (206.53) 1628 (208.42)
IIb 192 2182 (229.01) 2155 (237.70) 2142 (232.77)
IIc 302 3513 (287.40) 3486 (294.87) 3485 (291.87)
IId 142 1645 (185.74) 1660 (190.01) 1657 (190.63)
IIe 224 2623 (232.30) 2648 (233.43) 2654 (234.64)
IIIa 132 1300 (166.88) 1353 (176.52) 1363 (177.98)
IIIb 158 1527 (169.04) 1615 (181.30) 1627 (178.89)
IIIc 226 2105 (181.25) 2201 (193.09) 2209 (191.32)
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Chapter 5
Discussion and Future Work
The standard response adaptive randomization procedure will be affected by the de-
layed primary endpoint. When there is a large delay time in the primary endpoint,
less information can be used in the randomization procedure, thus the benefit of
assigning more patients to a better treatment group decreases. A surrogate endpoint
is a measurement made after the treatment to determine whether the treatment is
working. Normally, a surrogate endpoint can be obtained earlier than the primary
endpoint. When surrogate endpoint becomes available, the information from the
surrogate endpoint is valuable and should not be ignored. Therefore, we proposed
two response adaptive randomization procedures which will connect the surrogate
endpoint with the primary endpoint through a statistical model and use the accu-
mulated information from both the surrogate and primary endpoints to skew the
allocation proportion.
We first proposed a response adaptive randomization for clinical trials with nor-
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mally distributed primary and surrogate endpoints. We connected the surrogate and
primary endpoints through a bivariate normal distribution model, and introduced a
Bayesian approach to estimate the unknown parameters. We then substituted the
mean and standard deviation of primary endpoint in the target allocation function
with the conditional mean and conditional variance of primary endpoint. As an-
ticipated, the proposed algorithm can assign more patients to the more efficacious
treatment group, and is more powerful than the traditional equal allocation ran-
domization procedure. In addition, our proposed algorithm has advantages over the
standard response adaptive randomization which is solely based on the information
from the primary endpoint. Compared to the standard RAR, our proposed response
adaptive randomization can allocate slightly more patients to the superior treatment
group, and is more robust when there is a large delay in the primary endpoint.
We then consider a clinical trial with survival responses. We proposed a response
adaptive randomization for clinical trials with survival primary endpoint and cate-
gorical surrogate endpoint. We modeled the relationship between the survival time
and surrogate endpoint through a mixture model, and obtained the posterior means
of parameters of interest through a Bayesian model. We then calculated the tar-
get allocation ratio using the posterior estimates of marginal mean survival times.
Through some simulations, we found that the proposed response adaptive can allo-
cate more patients to a better performance treatment group, decrease the average
number of events (deaths), and maintain a comparable power as compared to the
traditional equal allocation randomization procedure. Meanwhile, compared to the
standard response adaptive randomization where only primary endpoint is used in
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the allocation procedure, our proposed algorithm is as effective as, and in most cases,
it performs even better in assigning subjects to better treatments.
There are some limitations with our proposed algorithm. First, both the two pro-
posed approaches assume that the surrogate endpoint can be observed before the next
patient coming in the trial, which is not always the case. In really clinical trials, most
of the surrogate endpoints cannot be observed immediately after the treatment, and
there is usually a lag time to observe a surrogate endpoint. Normally, the surrogate
endpoint can be obtained much sooner than the primary endpoint. Therefore, it will
be more appropriate to model the delay in both the primary and surrogate endpoint.
For example, we can assume that the delay time has an exponential distribution,
and the mean delay time in the surrogate endpoint is less than that in the primary
endpoint. Second, our proposed algorithm only considered one surrogate endpoint.
And for normally distributed primary endpoint, we assume the surrogate endpoint
also has a normal distribution; for survival responses, we assume that the surrogate
endpoint has a multinomial distribution. However, one may have more than one
surrogate endpoint available, and these surrogate endpoints may have distributions
other than normal and multinomial. Thus, in the future, we can consider more than
one surrogate endpoint with some other distributions. Third, in chapter 3, we con-
sidered a clinical trial with normally distributed primary and surrogate endpoints.
We investigated the performance of our proposed algorithm under different correla-
tions between the surrogate and primary endpoint, and found that the correlation
does not have an impact on the performance. As we know, the correlation measures
the linear relationship between the two variables. Instead of using the correlation,
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we can consider the concordance between the surrogate and primary endpoint in the
randomization procedure. Different from the correlation, the concordance measures
the agreement between two measurements. A strong linear correlation between two
variables does not mean there is also a strong concordance. Therefore, we may in-
vestigate the performance of our proposed algorithm under different concordance in
the future. Fourth, in the simulation study for both normally and exponentially
distributed primary outcomes, we only looked at a small number of scenarios. In
the future, we may want to change the parameter setups so we can evaluate the
performance of our proposed algorithm under more scenarios. Fifth, in the doubly
adaptive biased coin design (DBCD), we used α = 2 as recommonded by Zhang and
Rosenberger. For the future works, we may want to look at some other choices of α
in the DBCD function. Finally, in the response adaptive randomization procedure,
the allocation of the next patient dependents on the performance of the previous
patients, and this may have a violation of the assumption that the patients in the
study are independent.
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Appendix A
Chapter 3 appendix
A.1 Bivariate normal distribution model in JAGS
1
2 model{
3
4 # set values for the parameters in the prior distribution
5 R[1,1] <- 1
6 R[1,2] <- 0
7 R[2,1] <- 0
8 R[2,2] <- 1
9 nu <- 4
10 mu0 [1] <- 0
11 mu0 [2] <- 0
12 lambda <- 0.001
13
14 #-------- likelihood ------------#
15
16 for (i in 1:N) {
17
18 # marginal distribution of the surrogate endpoint
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19 Sdata[i] ~ dnorm(mu[1], taus)
20
21 # conditional mean of primary given surrogate
22 muTgvS[i] <- mu[2] + T*(Sdata[i] - mu[1])
23 # conditional distribution of primary endpoint given surrogate
24 Tdata[i] ~ dnorm(muTgvS[i], tauTgvS)
25 }
26
27 # Gamma prior distribution on marginal precision of S
28 as <- (nu -1)/2
29 bs <- R[1,1]/2
30 taus ~ dgamma(as, bs)
31
32 # Gamma prior distribution on conditional precision of Primary given surrogate
33 at <- nu/2
34 bt1 <- R[2,2] - (R[2,1])^2/R[1,1]
35 bt <- bt1/2
36 tauTgvS ~ dgamma(at , bt)
37
38 # Normal prior distribution on Omega_st , where Omega_st is a scalar
39 prmean <- R[1,2] / R[1,1]
40 prprec <- R[1,1] * tauTgvS
41 T ~ dnorm(prmean , prprec)
42
43 #---------- transformations to quantities of interest ------------#
44 # variance of S
45 Sigma [1,1] <- 1/taus
46 # Covariance between S and T
47 Sigma [1,2] <- T*Sigma [1,1]
48 # Variance of T
49 Sigma [2,2] <- 1/tauTgvS + (Sigma [1,2])^2/Sigma [1,1]
50 Sigma [2,1] <- Sigma [1,2]
51
52 # normal prior for mean vectors
53 tau.mu <- inverse(Sigma)*lambda
97
54 mu ~ dmnorm(mu0 , tau.mu)
55
56 }
A3 1.R
A.2 Proposed response adaptive randomization pro-
cedure for normally distributed primary out-
come
1 continuous.randomization <-function(isim.start , # start from zero
2 seed , # used in sed.seed function
3 nSims , # number of simulation
4 nSbjs , # total number of patients in the trial
5 n.init , # number of subjects in the equal randomizaition
6 alpha , # nonnegative number in DBCD procedure
7 Chi_square , # Chi -square for the hypothesis test
8 lambda1 , # delay time of primary endpoint for treatment A
9 lambda2 , # delay time of primary endpoint for treatment B
10 lambda3 , # entry time for both treatment groups
11 mu.SA, mu.SB, mu.TA, mu.TB ,
12 sigma.SSA , sigma.SSB , sigma.TTA , sigma.TTB , corr) {
13
14 allocation.prob.matrix = matrix(, nrow=nSims -isim.start , ncol=nSbjs)
15
16 power = {}
17 expected.response = {}
18 N.A.final.vec = {}
19 N.B.final.vec = {}
20 allocation.prop.final.vec = {}
21 TS.vec = {}
98
22 convergence.A.vec = {}
23 convergence.B.vec = {}
24
25 mu.A <- c(mu.SA, mu.TA) # mean vector that used to simulate surrogate and primary
endpoint for treatment A
26 mu.B <- c(mu.SB, mu.TB)
27
28 sigma.STA <- corr*sqrt(sigma.SSA)*sqrt(sigma.TTA)
29 sigma.STB <- corr*sqrt(sigma.SSB)*sqrt(sigma.TTB)
30 Sigma.A <- matrix(c(sigma.SSA , sigma.STA , sigma.STA , sigma.TTA), 2, 2) #
Covariance matrix for treatment A
31 Sigma.B <- matrix(c(sigma.SSB , sigma.STB , sigma.STB , sigma.TTB), 2, 2)
32
33 ##################################################
34 ################# DBCD procedure #################
35 ##################################################
36
37 DBCD <- function(muA , sigmaA , muB , sigmaB , alpha , N.A, N.B) {
38 if (is.na(muA) | is.na(muB) | is.na(sigmaA) | is.na(sigmaB) | muA < 0 | muB < 0)
{
39 g.function = 0.5
40 } else {
41 r = sigmaA*sqrt(muB)/sigmaB/sqrt(muA)
42 s = ifelse(muA < muB & r >1 | muA > muB & r<1, 1, 0)
43 rho = ifelse(s==1, sigmaA*sqrt(muB)/(sigmaA*sqrt(muB)+sigmaB*sqrt(muA)), 0.5)
44 x <- N.A/(N.A+N.B)
45 y <- rho
46 if (x==0) {
47 g.function = 1
48 } else if (x==1) {
49 g.function = 0
50 } else{
51 g.function = y*(y/x)^alpha/(y*(y/x)^alpha+(1-y)*((1-y)/(1-x))^alpha)
52 }
53 }
99
54 return(g.function)
55 }
56
57
58 set.seed(seed+isim.start)
59
60 for (isim in (isim.start +1):nSims) {
61
62 S.data = {} # surrogate endpoint
63 T.data = {} # primary endpoint
64 trt = {} # treatment indicator
65 et = {} # entry time
66 et.interval = {}
67 dt.interval = {}
68 dt = {} # observed time
69 #delta = {} # indicator variable that equals to 1 if the primary endpoint is
observed
70
71 convergence.A = {}
72 convergence.B = {}
73
74 ##### first , assign n.init subjects to each treatment , and assume that the 2*n.
init subjects ’ primary outcome and surrogate outcome are available
immediately.
75
76 for (i.equal in 1:(2*n.init)) {
77 # first , record the patient ’s entry time
78 entry.t <- rexp(1,1/lambda3)
79 et.interval <- rbind(et.interval , entry.t)
80
81 U = runif(1, min=0, max =1)
82 if(U < 0.5) {
83 A.init = mvrnorm(1, mu.A, Sigma.A)
84 S.data = rbind(S.data , A.init [1])
85 T.data = rbind(T.data , A.init [2])
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86 trt = rbind(trt , 1)
87
88 # simulate the delay time for this patient
89 delay.t <- rexp(1, 1/lambda1)
90 dt.interval <- rbind(dt.interval , delay.t)
91
92 et = rbind(et , 0)
93 dt = rbind(dt , 0)
94 #delta = rbind(delta , 1)
95 } else {
96 B.init = mvrnorm(1, mu.B, Sigma.B)
97 S.data = rbind(S.data , B.init [1])
98 T.data = rbind(T.data , B.init [2])
99 trt = rbind(trt , 2)
100
101 # simulate the delay time for this patient
102 delay.t <- rexp(1, 1/lambda2)
103 dt.interval <- rbind(dt.interval , delay.t)
104
105 et = rbind(et , 0)
106 dt = rbind(dt , 0)
107 #delta = rbind(delta , 1)
108 }
109 }
110
111 ## entry time and observed time
112 et[1] = et.interval [1]
113 dt[1] = et[1] + dt.interval [1]
114 for (i in 2:(2*n.init)) {
115 et[i] = et[i-1] + et.interval[i]
116 dt[i] = et[i] +dt.interval[i]
117 }
118
119 #### randomization procedure
120 for (iSbj in (2*n.init +1):nSbjs) {
101
121
122 # first , record the patient ’s entry time
123 entry.t <- rexp(1,1/lambda3)
124 et.interval <- rbind(et.interval , entry.t)
125 et[iSbj] <- et[iSbj -1]+ entry.t
126
127 # then we need to update the indicator variable delta before we assign this
patient
128 threshold <- et[iSbj]
129 delta <- ifelse(dt <=threshold , 1, 0)
130
131 ##########################################################################
132 ## For treatment A and B, get the posterior means for each parameters ####
133 ##########################################################################
134 SA.data <- S.data[trt ==1]
135 TA.data <- T.data[trt ==1]
136 delta.A <- delta[trt ==1]
137 TA.data[delta.A==0] <- NA
138 gibbs.data.A <- list(Sdata=SA.data , Tdata=TA.data , N=length(SA.data))
139 inits.A <- list(list(mu=c(0,0), taus=1, tauTgvS=1, T=0, .RNG.seed =12345 ,
140 .RNG.name="base::Mersenne -Twister"),
141 list(mu=c(2,1), taus =0.5, tauTgvS =0.5, T=0.5, .RNG.seed
=123456 ,
142 .RNG.name="base::Mersenne -Twister"),
143 list(mu=c(1,2), taus=2, tauTgvS =1.5, T=1, .RNG.seed
=1234,
144 .RNG.name="base::Mersenne -Twister"))
145 gibbs.jags.A <- jags.model(file="gibbs_wishart.bug", n.chains=3, inits=
inits.A, data=gibbs.data.A)
146 gibbs.out.A <- coda.samples(gibbs.jags.A, n.iter=5E3 , thin=2, variable.
names=c("mu", "taus", "tauTgvS", "T"))
147 gelman.A <- gelman.diag(gibbs.out.A, multivariate=FALSE)
148 convergence.A.psrf <- ifelse(gelman.A$psrf[,1]<1.1, 0, 1)
149 convergence.A.ind <- sum(convergence.A.psrf)
150 convergence.A <- rbind(convergence.A, convergence.A.ind)
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151 out.A <- summary(gibbs.out.A)
152 T.A <- out.A$statistics [1,1]
153 sigmaTgvS.A <- 1/out.A$statistics [4,1]
154 sigmaTgvS.A.sqrt <- sqrt(sigmaTgvS.A)
155 muT.A <- out.A$statistics [3,1]
156 muS.A <- out.A$statistics [2,1]
157 muTgvS.A <- muT.A + T.A*(mean(SA.data)-muS.A)
158 N.A <- length(SA.data)
159
160 SB.data <- S.data[trt ==2]
161 TB.data <- T.data[trt ==2]
162 delta.B <- delta[trt ==2]
163 TB.data[delta.B==0] <- NA
164 gibbs.data.B <- list(Sdata=SB.data , Tdata=TB.data , N=length(SB.data))
165 inits.B <- list(list(mu=c(0,0), taus=1, tauTgvS=1, T=0, .RNG.seed =12345 ,
166 .RNG.name="base::Mersenne -Twister"),
167 list(mu=c(2,1), taus =0.5, tauTgvS =0.5, T=0.5, .RNG.seed
=123456 ,
168 .RNG.name="base::Mersenne -Twister"),
169 list(mu=c(1,2), taus=2, tauTgvS =1.5, T=1, .RNG.seed
=1234,
170 .RNG.name="base::Mersenne -Twister"))
171 gibbs.jags.B <- jags.model(file="gibbs_wishart.bug", n.chains=3, inits=
inits.B, data=gibbs.data.B)
172 gibbs.out.B <- coda.samples(gibbs.jags.B, n.iter=5E3 , thin=2, variable.
names=c("mu", "taus", "tauTgvS", "T"))
173 gelman.B <- gelman.diag(gibbs.out.B, multivariate=FALSE)
174 convergence.B.psrf <- ifelse(gelman.B$psrf[,1]<1.1, 0, 1)
175 convergence.B.ind <- sum(convergence.B.psrf)
176 convergence.B <- rbind(convergence.B, convergence.B.ind)
177 out.B <- summary(gibbs.out.B)
178 T.B <- out.B$statistics [1,1]
179 sigmaTgvS.B <- 1/out.B$statistics [4,1]
180 sigmaTgvS.B.sqrt <- sqrt(sigmaTgvS.B)
181 muT.B <- out.B$statistics [3,1]
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182 muS.B <- out.B$statistics [2,1]
183 muTgvS.B <- muT.B + T.B*(mean(SB.data)-muS.B)
184 N.B <- length(SB.data)
185
186 # calculate the allocation ratio , and then do the randomization process
187 U = runif(1,min=0, max=1)
188
189 allocation.interim = DBCD(muA=muTgvS.A, sigmaA=sigmaTgvS.A.sqrt , muB=muTgvS.B,
sigmaB=sigmaTgvS.B.sqrt , alpha=alpha , N.A=N.A, N.B=N.B)
190
191 allocation.prob.matrix[isim -isim.start , iSbj] = allocation.interim
192
193 if (U < allocation.interim) {
194 # allocate this patient to trt A
195 sim.A <- mvrnorm(n=1, mu=mu.A, Sigma=Sigma.A)
196 S.data = rbind(S.data , sim.A[1])
197 T.data = rbind(T.data , sim.A[2])
198 trt = rbind(trt , 1)
199
200 # simulate the delay time for this patient
201 delay.t <- rexp(1, 1/lambda1)
202 dt.interval <- rbind(dt.interval , delay.t)
203 dt[iSbj] <- et[iSbj] + delay.t
204
205 } else {
206 sim.B <- mvrnorm(n=1, mu=mu.B, Sigma=Sigma.B)
207 S.data = rbind(S.data , sim.B[1])
208 T.data = rbind(T.data , sim.B[2])
209 trt = rbind(trt , 2)
210
211 # simulate the delay time for this patient
212 delay.t <- rexp(1, 1/lambda2)
213 dt.interval <- rbind(dt.interval , delay.t)
214 dt[iSbj] <- et[iSbj] + delay.t
215 }
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216 }
217
218 ######################################################################
219 ##### point estimate of mean and variance ############################
220 ######################################################################
221 data.final.A <- T.data[trt ==1]
222 data.final.B <- T.data[trt ==2]
223 N.A.final <- length(data.final.A)
224 N.B.final <- length(data.final.B)
225 mu.A.est <- mean(data.final.A)
226 mu.B.est <- mean(data.final.B)
227 sigma2.A.est <- var(data.final.A)
228 sigma2.B.est <- var(data.final.B)
229
230 TS = (mu.A.est - mu.B.est)^2/(sigma2.A.est/N.A.final + sigma2.B.est/N.B.final)
231 TS.vec = rbind(TS.vec , TS)
232
233 N.A.final.vec <- rbind(N.A.final.vec , N.A.final)
234 N.B.final.vec <- rbind(N.B.final.vec , N.B.final)
235
236 allocation.prop.final <- N.A.final/(N.A.final+N.B.final)
237 allocation.prop.final.vec <- rbind(allocation.prop.final.vec , allocation.prop.
final)
238
239 sd.A.est <- sqrt(sigma2.A.est)
240 sd.B.est <- sqrt(sigma2.B.est)
241
242 total.response <- sum(T.data)
243 #total.response <- (N.A.final+N.B.final)*(rho.hat*mu.A.est+(1-rho.hat)*mu.B.est)
244 expected.response <- rbind(expected.response , total.response)
245
246 ## convergence
247 convergence.A.vec <- rbind(convergence.A.vec , sum(convergence.A))
248 convergence.B.vec <- rbind(convergence.B.vec , sum(convergence.B))
249 }
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250
251 power = ifelse(TS.vec > Chi_square , 1, 0)
252 power.est = sum(power)/length(power)
253 N.A.est = mean(N.A.final.vec)
254 N.B.est = mean(N.B.final.vec)
255 #rho.est = mean(rho.final)
256 total.est = mean(expected.response)
257
258 list(power.est=power.est , N.A.est=N.A.est , N.B.est=N.B.est , total.est=total.est ,
259 N.A.final.vec = N.A.final.vec , N.B.final.vec = N.B.final.vec , allocation.prop
.final.vec = allocation.prop.final.vec , expected.response = expected.
response , allocation.prob.matrix=allocation.prob.matrix ,
260 TS.vec = TS.vec , power=power , power.est=power.est , convergence.A.vec =
convergence.A.vec , convergence.B.vec = convergence.B.vec)
261
262
263 }
A3 2.R
106
Appendix B
Chapter 4 appendix
B.1 Mixture model in JAGS
1 model {
2 ## likelihood
3 for (i in 1:N) {
4 is.censored[i] ~ dinterval(t.to.event[i], t.cen[i])
5 t.to.event[i] ~ dexp(lambda[i])
6 lambda[i] <- lambda.vec[surrogate[i]]
7 surrogate[i] ~ dcat(pi [1:2])
8 }
9
10 ## prior
11 pi[1:2] ~ ddirch(gamma [])
12 tau ~ dgamma (11, 280)
13 lambda.vec [2] ~ dgamma (11, 70)
14
15 theta.vec[2] <- 1/lambda.vec [2]
16 diff <- 1/tau
17 theta.vec[1] <- theta.vec[2] + diff
18 lambda.vec [1] <- 1/theta.vec[1]
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19
20
21 }
B4 1.R
B.2 Proposed response adaptive randomization pro-
cedure for survival response
1 survival.randomization <- function(isim.start , # start from zero
2 seed , # used in set.seed function
3 nSims , # number of simulations
4 nSbjs , # total number of patients in the trial
5 n.init , # number of subjects in the equal
randomizaition
6 alpha , # nonnegative number in the DBCD procedure
7 weight1.A, weight2.A,
8 weight1.B, weight2.B,
9 theta1.A, theta2.A, # mean survival time
10 theta1.B, theta2.B,
11 R, # patient arrival times follow uniform dist on
[0, R]
12 D,
13 n.iter , n.thin , n.update) {
14
15 allocation.prob.matrix = matrix(, nrow=nSims -isim.start , ncol=nSbjs)
16
17 p.val.vec = {}
18 z.score.vec = {}
19 num.event.vec = {}
20 total.obs.surv.time.vec = {}
21 allocation.prop.final.vec = {}
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22 N.A.final.vec = {}
23 N.B.final.vec = {}
24 convergence.A.vec = {}
25 convergence.B.vec = {}
26
27 convergence.theta1.A.vec = {}
28 convergence.theta2.A.vec = {}
29 convergence.pi1.A.vec = {}
30 convergence.pi2.A.vec = {}
31
32 convergence.theta1.B.vec = {}
33 convergence.theta2.B.vec = {}
34 convergence.pi1.B.vec = {}
35 convergence.pi2.B.vec = {}
36
37 epsilon.final.A.vec = {}
38 epsilon.final.B.vec = {}
39
40 ####### target allocation proportion function ############################
41 #rho <- function(Psi.A, Psi.B, variance.A, variance.B) { #
42 # sd.A = sqrt(variance.A) #
43 # sd.B = sqrt(variance.B) #
44 # rho = (sd.A*sqrt(Psi.B))/(sd.A*sqrt(Psi.B)+sd.B*sqrt(Psi.A)) #
45 # return(rho) #
46 #} #
47 #########################################################################
48
49 ######## the DBCD procedure
50 DBCD <- function(Psi.A, Psi.B, variance.A, variance.B, N.A, N.B) {
51 if (is.na(Psi.A) | is.na(Psi.B)) {
52 g.function = 0.5
53 } else {
54 sd.A = sqrt(variance.A)
55 sd.B = sqrt(variance.B)
56 x = N.A/(N.A+N.B)
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57 y = (sd.A*sqrt(Psi.B))/(sd.A*sqrt(Psi.B)+sd.B*sqrt(Psi.A))
58 if (x==0) {
59 g.function = 1
60 } else if (x==1) {
61 g.function = 0
62 } else{
63 g.function = y*(y/x)^alpha/(y*(y/x)^alpha+(1-y)*((1-y)/(1-x))^alpha)
64 }
65 }
66
67 return(g.function)
68 }
69
70 ######## expected proportion of event function
71 epsilon <- function(theta , D, R) {
72 epsilon = 1 - theta/D + exp(-D/theta)*theta/(D*R)*(exp(R/theta)*(2*theta -R)-2*
theta)
73 return(epsilon)
74 }
75
76 jags.params <- c(’lambda.vec’, ’pi’, ’theta.vec’, ’tau’)
77
78 set.seed(seed+isim.start)
79
80 for (isim in (isim.start +1):nSims) {
81
82 surrogate = {} # surrogate endpoint
83 event.time = {} # event time
84 trt = {}
85 #trt.A = {}
86 #trt.B = {}
87 censor.time = {}
88
89 convergence.A = {}
90 convergence.B = {}
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91
92 convergence.theta1.A = {}
93 convergence.theta2.A = {}
94 convergence.pi1.A = {}
95 convergence.pi2.A = {}
96
97 convergence.theta1.B = {}
98 convergence.theta2.B = {}
99 convergence.pi1.B = {}
100 convergence.pi2.B = {}
101
102
103 #### first , generate the patient arrival time for all the patients
104 arrival.time.disorder <- runif(nSbjs , 0, R)
105 arrival.time = arrival.time.disorder[order(arrival.time.disorder)]
106
107 for (iSbj in 1:nSbjs) {
108
109 censor.time.interim = ifelse(censor.time < arrival.time[iSbj], censor.time ,
arrival.time[iSbj])
110 t.to.event.interim = pmin(event.time , censor.time.interim)
111 isCensored.interim = event.time > censor.time.interim
112 is.censored.interim = as.numeric(isCensored.interim)
113 is.event.interim = 1 - is.censored.interim
114 t.cen.interim <- t.to.event.interim
115 t.to.event.na.interim = t.to.event.interim
116 t.to.event.na.interim[is.censored.interim ==1] <- NA
117
118 surrogate.interim.A = surrogate[trt ==1]
119 surrogate.interim.B = surrogate[trt ==2]
120
121 t.to.event.na.interim.A = t.to.event.na.interim[trt ==1]
122 t.to.event.na.interim.B = t.to.event.na.interim[trt ==2]
123
124 t.cen.interim.A = t.cen.interim[trt ==1]
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125 t.cen.interim.B = t.cen.interim[trt ==2]
126
127 is.censored.interim.A = is.censored.interim[trt ==1]
128 is.censored.interim.B = is.censored.interim[trt ==2]
129
130 is.event.interim.A = is.event.interim[trt ==1]
131 is.event.interim.B = is.event.interim[trt ==2]
132
133 N.A.interim = length(surrogate.interim.A)
134 N.B.interim = length(surrogate.interim.B)
135
136 U = runif(1, 0, 1)
137
138 if (N.A.interim ==0 | N.B.interim ==0 | sum(is.event.interim.A) < 3 | sum(is.
event.interim.B) < 3) {
139 # equal randomization
140 allocation.prob.matrix[isim -isim.start , iSbj] = 0.5
141 if (U < 0.5) {
142 surrogate.A <- rbinom(1, 1, weight1.A)
143 surrogate.A = ifelse(surrogate.A==1, 1, 2)
144 surrogate = rbind(surrogate , surrogate.A)
145 event.time.A <- ifelse(surrogate.A==1, rexp(1, 1/theta1.A), rexp(1, 1/
theta2.A))
146 event.time = rbind(event.time , event.time.A)
147 trt = rbind(trt , 1)
148 } else {
149 surrogate.B <- rbinom(1, 1, weight1.B)
150 surrogate.B = ifelse(surrogate.B==1, 1, 2)
151 surrogate = rbind(surrogate , surrogate.B)
152 event.time.B <- ifelse(surrogate.B==1, rexp(1, 1/theta1.B), rexp(1, 1/
theta2.B))
153 event.time = rbind(event.time , event.time.B)
154 trt = rbind(trt , 2)
155 }
156 } else {
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157 # adaptive randomization
158 ####### initial values for the Bayesian model
159 yInit.A = rep(NA , length(surrogate.interim.A))
160 yInit.A[is.censored.interim.A==1] = t.cen.interim.A[is.censored.interim.A
==1]+1
161
162 inits.A <- list(list(pi=c(0.7, 0.3), lambda.vec=c(NA, 0.02), tau =0.03 , t.to.
event=yInit.A, .RNG.seed =12345 , .RNG.name="base::Mersenne -Twister"),
163 list(pi=c(0.8, 0.2), lambda.vec=c(NA, 0.03), tau=0.02, t.to.
event=yInit.A, .RNG.seed =1234 , .RNG.name="base::Mersenne -
Twister"),
164 list(pi=c(0.5, 0.5), lambda.vec=c(NA, 0.05), tau=0.01, t.to.
event=yInit.A, .RNG.seed =123456 , .RNG.name="base::Mersenne
-Twister"))
165
166 gibbs.data.A <- list(t.to.event = t.to.event.na.interim.A, t.cen = t.cen.
interim.A, is.censored = is.censored.interim.A, N = length(t.to.event.na
.interim.A), surrogate = surrogate.interim.A, gamma = c(0.5, 0.5))
167
168 gibbs.jags.A <- jags(data = gibbs.data.A, inits = inits.A, parameters.to.
save = jags.params , n.iter = n.iter , model.file = ’survival.bug’, n.thin
=n.thin)
169
170 jagsfit.upd.A <- autojags(gibbs.jags.A, n.update=n.update)
171 myfit.A <- as.mcmc(jagsfit.upd.A)
172 out.A <- summary(myfit.A)
173
174 myfit.list.A <- mcmc.list(myfit.A)
175 gelman.A <- gelman.diag(myfit.list.A, multivariate=FALSE)
176 convergence.theta1.A.interim <- ifelse(gelman.A$psrf [7,1]<=1.1, 0, 1)
177 convergence.theta2.A.interim <- ifelse(gelman.A$psrf [8,1]<=1.1, 0, 1)
178 convergence.pi1.A.interim <- ifelse(gelman.A$psrf [4,1]<=1.1, 0, 1)
179 convergence.pi2.A.interim <- ifelse(gelman.A$psrf [5,1]<=1.1, 0, 1)
180 convergence.A.psrf <- ifelse(gelman.A$psrf[c(2,3,6) ,1]<=1.1, 0, 1)
181 convergence.A.ind <- sum(convergence.A.psrf)
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182 convergence.A <- rbind(convergence.A, convergence.A.ind)
183 convergence.theta1.A <- rbind(convergence.theta1.A, convergence.theta1.A.
interim)
184 convergence.theta2.A <- rbind(convergence.theta2.A, convergence.theta2.A.
interim)
185 convergence.pi1.A <- rbind(convergence.pi1.A, convergence.pi1.A.interim)
186 convergence.pi2.A <- rbind(convergence.pi2.A, convergence.pi2.A.interim)
187
188 theta .1. interim.A = out.A$statistics [7,1]
189 theta .2. interim.A = out.A$statistics [8,1]
190 weight .1. interim.A = out.A$statistics [4,1]
191 weight .2. interim.A = out.A$statistics [5,1]
192 theta.interim.A = weight .1. interim.A*theta .1. interim.A+weight .2. interim.A*
theta .2. interim.A ## mean survival time
193 variance.interim.A = theta.interim.A^2
194 epsilon.interim.A = epsilon(theta=theta.interim.A, D=D, R=R)
195 variance.interim.censor.A = variance.interim.A/epsilon.interim.A
196 N.A.interim = length(surrogate.interim.A)
197
198 ## for treatment B
199 ####### initial values for the Bayesian model
200 yInit.B = rep(NA , length(surrogate.interim.B))
201 yInit.B[is.censored.interim.B==1] = t.cen.interim.B[is.censored.interim.B
==1]+1
202
203 inits.B <- list(list(pi=c(0.7, 0.3), lambda.vec=c(NA, 0.02), tau =0.03 , t.to.
event=yInit.B, .RNG.seed =12345 , .RNG.name="base::Mersenne -Twister"),
204 list(pi=c(0.8, 0.2), lambda.vec=c(NA, 0.03), tau=0.02, t.to.
event=yInit.B, .RNG.seed =1234 , .RNG.name="base::Mersenne -
Twister"),
205 list(pi=c(0.5, 0.5), lambda.vec=c(NA, 0.05), tau=0.01, t.to.
event=yInit.B, .RNG.seed =123456 , .RNG.name="base::Mersenne
-Twister"))
206
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207 gibbs.data.B <- list(t.to.event = t.to.event.na.interim.B, t.cen = t.cen.
interim.B, is.censored = is.censored.interim.B, N = length(t.to.event.na
.interim.B), surrogate = surrogate.interim.B, gamma = c(0.5, 0.5))
208
209 gibbs.jags.B <- jags(data = gibbs.data.B, inits = inits.B, parameters.to.
save = jags.params , n.iter = n.iter , model.file = ’survival.bug’, n.thin
=n.thin)
210
211 jagsfit.upd.B <- autojags(gibbs.jags.B, n.update=n.update)
212 myfit.B <- as.mcmc(jagsfit.upd.B)
213 out.B <- summary(myfit.B)
214
215 myfit.list.B <- mcmc.list(myfit.B)
216 gelman.B <- gelman.diag(myfit.list.B, multivariate=FALSE)
217 convergence.theta1.B.interim <- ifelse(gelman.B$psrf [7,1]<=1.1, 0, 1)
218 convergence.theta2.B.interim <- ifelse(gelman.B$psrf [8,1]<=1.1, 0, 1)
219 convergence.pi1.B.interim <- ifelse(gelman.B$psrf [4,1]<=1.1, 0, 1)
220 convergence.pi2.B.interim <- ifelse(gelman.B$psrf [5,1]<=1.1, 0, 1)
221 convergence.B.psrf <- ifelse(gelman.B$psrf[c(2,3,6) ,1]<=1.1, 0, 1)
222 convergence.B.ind <- sum(convergence.B.psrf)
223 convergence.B <- rbind(convergence.B, convergence.B.ind)
224 convergence.theta1.B <- rbind(convergence.theta1.B, convergence.theta1.B.
interim)
225 convergence.theta2.B <- rbind(convergence.theta2.B, convergence.theta2.B.
interim)
226 convergence.pi1.B <- rbind(convergence.pi1.B, convergence.pi1.B.interim)
227 convergence.pi2.B <- rbind(convergence.pi2.B, convergence.pi2.B.interim)
228
229 theta .1. interim.B = out.B$statistics [7,1] # mean survival time
230 theta .2. interim.B = out.B$statistics [8,1]
231 weight .1. interim.B = out.B$statistics [4,1]
232 weight .2. interim.B = out.B$statistics [5,1]
233 theta.interim.B = weight .1. interim.B*theta .1. interim.B + weight .2. interim.B*
theta .2. interim.B ## mean survival time
234 variance.interim.B = theta.interim.B^2
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235 epsilon.interim.B = epsilon(theta=theta.interim.B, D=D, R=R)
236 variance.interim.censor.B = variance.interim.B/epsilon.interim.B
237 N.B.interim = length(surrogate.interim.B)
238
239 ## update the allocation ratio before randomize the next subject
240 Psi.interim.A = 1/theta.interim.A
241 Psi.interim.B = 1/theta.interim.B
242 allocation.interim = DBCD(Psi.A=Psi.interim.A, Psi.B=Psi.interim.B, variance
.A=variance.interim.censor.A, variance.B=variance.interim.censor.B, N.A=
N.A.interim , N.B=N.B.interim)
243
244 allocation.prob.matrix[isim -isim.start , iSbj] = allocation.interim
245
246 if (U < allocation.interim) {
247 ## allocate this patient to trt A
248 surrogate.A <- rbinom(1, 1, weight1.A)
249 surrogate.A = ifelse(surrogate.A==1, 1, 2)
250 surrogate = rbind(surrogate , surrogate.A)
251 event.time.A <- ifelse(surrogate.A==1, rexp(1, 1/theta1.A), rexp(1, 1/
theta2.A))
252 event.time = rbind(event.time , event.time.A)
253 trt = rbind(trt , 1)
254 } else {
255 ## allocate this patient to trt B
256 surrogate.B <- rbinom(1, 1, weight1.B)
257 surrogate.B = ifelse(surrogate.B==1, 1, 2)
258 surrogate = rbind(surrogate , surrogate.B)
259 event.time.B <- ifelse(surrogate.B==1, rexp(1, 1/theta1.B), rexp(1, 1/
theta2.B))
260 event.time = rbind(event.time , event.time.B)
261 trt = rbind(trt , 2)
262 }
263 }
264 ## simulate the censoring time for this patient
265 censor.time.i = runif(1, min=0, max=D)
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266 censor.time = rbind(censor.time , censor.time.i)
267 }
268
269 ### update the data for the last subject
270 censor.time.final = ifelse(censor.time < D, censor.time , D)
271 t.to.event.final = pmin(event.time , censor.time.final)
272 is.censored.final = ifelse(t.to.event.final == censor.time.final , 1, 0)
273 is.event.final = 1 - is.censored.final
274
275 ### log rank test
276 test <- survdiff(Surv(t.to.event.final , is.event.final) ~ trt , rho = 0)
277 p.val <- 1 - pchisq(test$chisq , length(test$n) - 1)
278 p.val.vec <- rbind(p.val.vec , p.val)
279
280 ### number of events in the trial
281 num.event <- sum(is.event.final)
282 num.event.vec <- rbind(num.event.vec , num.event)
283
284 ### total observed survival time
285 total.obs.surv.time <- sum(t.to.event.final*is.event.final)
286 total.obs.surv.time.vec <- rbind(total.obs.surv.time.vec , total.obs.surv.time)
287
288 #############################################################################
289 ########### point estimate of hazard based on primary endpint ###############
290 #############################################################################
291 t.to.event.final.A <- as.vector(t.to.event.final)[trt ==1]
292 t.to.event.final.B <- as.vector(t.to.event.final)[trt ==2]
293 is.event.final.A <- as.vector(is.event.final)[trt ==1]
294 is.event.final.B <- as.vector(is.event.final)[trt ==2]
295 N.A.final <- length(t.to.event.final.A)
296 N.B.final <- length(t.to.event.final.B)
297
298 N.A.final.vec <- rbind(N.A.final.vec , N.A.final)
299 N.B.final.vec <- rbind(N.B.final.vec , N.B.final)
300
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301 ### maximum likelihood estimator
302 theta.marginal.final.A <- sum(t.to.event.final.A)/sum(is.event.final.A)
303 theta.marginal.final.B <- sum(t.to.event.final.B)/sum(is.event.final.B)
304
305 epsilon.final.A <- epsilon(theta=theta.marginal.final.A, D, R)
306 epsilon.final.B <- epsilon(theta=theta.marginal.final.B, D, R)
307
308 epsilon.final.A.vec <- rbind(epsilon.final.A.vec , epsilon.final.A)
309 epsilon.final.B.vec <- rbind(epsilon.final.B.vec , epsilon.final.B)
310
311 ### allocation proportion
312 allocation.prop.final <- N.A.final/(N.A.final+N.B.final)
313 allocation.prop.final.vec <- rbind(allocation.prop.final.vec , allocation.prop.
final)
314
315 ### wald test
316 z.score <- (theta.marginal.final.A-theta.marginal.final.B)/sqrt(theta.marginal.
final.A^2/sum(is.event.final.A)+theta.marginal.final.B^2/sum(is.event.final.
B))
317 z.score.vec <- rbind(z.score.vec , z.score)
318
319 ### convergence
320 convergence.A.vec <- rbind(convergence.A.vec , sum(convergence.A))
321 convergence.B.vec <- rbind(convergence.B.vec , sum(convergence.B))
322
323 convergence.theta1.A.vec <- rbind(convergence.theta1.A.vec , sum(convergence.
theta1.A))
324 convergence.theta2.A.vec <- rbind(convergence.theta2.A.vec , sum(convergence.
theta2.A))
325 convergence.pi1.A.vec <- rbind(convergence.pi1.A.vec , sum(convergence.pi1.A))
326 convergence.pi2.A.vec <- rbind(convergence.pi2.A.vec , sum(convergence.pi2.A))
327
328 convergence.theta1.B.vec <- rbind(convergence.theta1.B.vec , sum(convergence.
theta1.B))
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329 convergence.theta2.B.vec <- rbind(convergence.theta2.B.vec , sum(convergence.
theta2.B))
330 convergence.pi1.B.vec <- rbind(convergence.pi1.B.vec , sum(convergence.pi1.B))
331 convergence.pi2.B.vec <- rbind(convergence.pi2.B.vec , sum(convergence.pi2.B))
332 }
333
334 test.result = ifelse(p.val.vec < 0.05, 1, 0)
335 power = sum(test.result)/length(test.result)
336 N.A.est = mean(N.A.final.vec)
337 N.B.est = mean(N.B.final.vec)
338 num.event.est = mean(num.event.vec)
339 total.obs.surv.time.est = mean(total.obs.surv.time.vec)
340 allocation.prop.est = mean(allocation.prop.final.vec)
341 epsilon.A.est = mean(epsilon.final.A.vec)
342 epsilon.B.est = mean(epsilon.final.B.vec)
343
344 list(power=power , N.A.est=N.A.est , N.B.est=N.B.est , num.event.est=num.event.est ,
total.obs.surv.time.est=total.obs.surv.time.est , allocation.prop.est=
allocation.prop.est , epsilon.A.est=epsilon.A.est , epsilon.B.est=epsilon.B.est ,
p.val.vec=p.val.vec , N.A.final.vec=N.A.final.vec , N.B.final.vec=N.B.final.vec
, allocation.prop.final.vec=allocation.prop.final.vec , convergence.A.vec=
convergence.A.vec , convergence.B.vec=convergence.B.vec , num.event.vec=num.
event.vec , total.obs.surv.time.vec=total.obs.surv.time.vec , epsilon.final.A.
vec=epsilon.final.A.vec , epsilon.final.B.vec=epsilon.final.B.vec , convergence.
theta1.A.vec=convergence.theta1.A.vec , convergence.theta2.A.vec=convergence.
theta2.A.vec , convergence.pi1.A.vec=convergence.pi1.A.vec ,
345 convergence.pi2.A.vec=convergence.pi2.A.vec , convergence.theta1.B.vec=convergence.
theta1.B.vec , convergence.theta2.B.vec=convergence.theta2.B.vec , convergence.
pi1.B.vec=convergence.pi1.B.vec ,
346 convergence.pi2.B.vec=convergence.pi2.B.vec , allocation.prob.matrix=allocation.
prob.matrix , z.score.vec = z.score.vec)
347
348
349 }
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B4 2.R
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